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ABSTRACT 
 
KIMBERLY A. PORTER: Challenges to the Treatment of Malaria 
(Under the direction of Steven Meshnick) 
 
 
Malaria remains a significant cause of morbidity and mortality.  Successful 
treatment of malaria is threatened by widespread drug resistance and co-infections 
with HIV. 
This dissertation explored two challenges to malaria treatment.  The first aim 
addressed outcome misclassification in antimalarial treatment trials.  Without 
accurate classification of patients’ outcomes, estimates of drug efficacy are flawed.  
We identified factors related to outcome misclassification: transmission intensity, the 
distribution of genetic variants in parasite populations, multiplicity of infection, and 
PCR-insensitivity to minority variants; then used our findings to develop a Monte 
Carlo uncertainty analysis.   
Using the uncertainty analysis, we found that misclassification of new 
infections as treatment failures was common and underestimated treatment efficacy in 
the high transmission area.  The initial estimate of the cure rate in the high 
transmission area was 63.8%; after adjustment for uncertainty related to outcome 
misclassification, the 95% simulation interval of the cure rate was 74.6 to 83.3%.  
The initial estimate of the cure rate in the low transmission area was 94.0%; after the 
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uncertainty adjustment the 95% simulation interval of the cure rate was 93.5 to 
96.5%.   
The second aim was to assess the effect of a co-formulation of HIV protease 
inhibitors (PI) on incidence of clinical malaria among HIV-infected adults.  
Laboratory evidence has demonstrated that HIV PIs inhibit growth of Plasmodium 
falciparum, a malaria-causing parasite.  We conducted an ancillary analysis of data 
collected by the Adult AIDS Clinical Trials Group in two trials comparing PI-based 
against non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral 
therapy on the incidence of clinical malaria in study participants residing in areas 
with endemic malaria. 
We used pooled logistic regression to calculate hazard ratios (HR) and 95% 
confidence intervals (CI).  There was no effect of PI-based therapy on incidence of 
clinical malaria (HR = 1.03, 95% CI (0.74 - 1.44)), nor was there modification of the 
HR by seasonality and use of concomitant medications. 
 Successful treatment of malaria is a global health priority.  This dissertation 
provides a novel way to estimate treatment efficacy and proposes that HIV PIs may 
not have antimalarial action in HIV-infected patients at risk of co-infection. 
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 CHAPTER 1 
 
INTRODUCTION AND LITERATURE REVIEW 
 
Malaria, a major cause of morbidity and mortality, is a mosquito-borne disease 
caused by Plasmodium parasites.  In 2008, there were an estimated 243 million cases of 
malaria resulting in 863,000 deaths worldwide.(1)  Malaria can be controlled through 
environmental modification and prevention strategies; it has been successfully eliminated 
from several regions of the world including the United States.  In parts of the developing 
world, however, particularly Sub-Saharan Africa and Southeast Asia, the burden of 
malaria remains immense. 
 P. falciparum is the most pathogenic of the five human disease-causing 
Plasmodium species and is the focus of this work; from this point forward, malaria will 
refer exclusively to infection with P. falciparum.  P. falciparum, which is transmitted by 
the Anopheles mosquito, is highly prevalent in Sub-Saharan Africa and is the most 
common Plasmodium species in tropical and subtropical regions.(2)  
 The life-cycle of Plasmodium is complex and requires both a mosquito and 
vertebrate host.  Different Plasmodium species have slightly different life-cycles; the 
following refers to P. falciparum.  In the mosquito, gametocyte-stage parasites ingested 
from the vertebrate host undergo sexual reproduction developing first into zygotes, then 
ookinetes, which eventually rupture releasing sporozoites.  This is known as the 
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sporogonic cycle and lasts roughly two to three weeks.  The sporozoites infect the 
vertebrate host through the salivary gland of the mosquito when it takes a blood meal.  
Once inside the vertebrate host, sporozoites infect liver cells where they develop into 
tissue schizonts.  Each tissue schizont undergoes asexual replication generating 
merozoites; this is known the exo-erythrocytic cycle.  Finally, the merozoite-stage 
parasites rupture the liver cell and infect red blood cells.  There they undergo asexual 
reproduction and develop into immature trophozoites (referred to as ring-stage parasites).  
At that time, the parasites develop into either gametocytes or mature trophozoites which 
then develop into erythrocytic schizonts.  The gametocytes are taken up by a feeding 
mosquito; the erythrocytic schizonts rupture and release merozoites which start the 
erythrocytic cycle again.  (Figure 1) 
 
Figure 1. The life-cycle of Plasmodium.(3) 
 Malaria transmission intensity varies regionally and often seasonally.  
Transmission intensity is commonly measured by the entomological inoculation rate 
(EIR) and multiplicity of infection (MOI).  The EIR estimates the number of 
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infectious bites per person-year and can differ greatly among locations.  During the 
rainy season in Uganda’s Tororo District, the EIR is estimated to be 591(4); in a 
semi-urban area in Burkina Faso, the EIR is believed to be under five.(5) MOI is the 
patient’s number of infections (identified by the number of genotypes in a blood 
sample) and is positively correlated with transmission intensity.  It is also inversely 
associated with the host’s level of acquired immunity.(6) Acquired immunity 
provides protection against malaria in individuals with regular exposure, i.e. those 
living in areas of stable or high transmission.  In such areas, clinical disease is far 
more common in children who do yet possess sufficient immunity, and pregnant 
women, as pregnancy reduces immunity to malaria.(7) In low transmission areas, less 
immunity develops and clinical disease is more likely to occur at any age.(8) 
 Host defenses associated with acquired immunity help protect against 
infection, control levels of parasitemia and reduce incidence of clinical disease.(9) It 
is believed that this is in large part due to humoral responses with antibodies 
appearing to target different parasite stages.(2)  
 In addition to the specificity of antibodies to different parasite stages, 
evidence suggests that acquired immunity may be strain-specific.(10)  Acquired 
immunity takes years to develop and is dependent upon transmission intensity; it does 
not alleviate the need for effective antimalarial treatments. 
Antimalarial drugs act against different parasite stages.  Many antimalarials target 
blood stage parasites.  These drugs include quinine, chloroquine, and the artemisinin 
derivatives (Arteether, Artesunate, Artemether).  Others target other parasite stages; 
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primaquine has anti-gametocyte action. Some drugs appear to target more than one stage.  
For example, primaquine also acts against tissue schizonts.(2)    
Antimalarials also have different half-lives and each may be particularly useful in 
certain circumstances.  Treatments with long half-lives, such as mefloquine, may confer 
longer lasting protection and be especially important in areas of high transmission as they 
may be better able to decrease reinfection.(11) Drugs that are highly efficacious against 
primary blood stage infection or have shorter half-lives, such as chlorproguanil/dapsone 
(LapDap) and the artemisinin derivatives, may play a particularly important role in 
reducing the clinical illness that occurs during primary infections.(11)   
Current malaria treatment strategies employ combinations of drugs to help slow 
development of drug resistance.  Artemisinin-based combination therapy (ACT) has 
demonstrated high efficacy; it consists of a short-lived, fast-acting artemisinin derivative 
partnered with a drug with a longer half-life to kill remaining parasites.(12) Care must be 
taken to select partner drugs to which parasites in the region remain sensitive.   
Determining which treatments remain effective can be done through clinical 
trials, public health surveillance and observational epidemiologic studies.  Much of this 
work is carried out in areas with high EIR; therefore to accurately assess the drug’s 
effect, these approaches require the ability to distinguish between reinfection and 
recrudescence.  Resistance can also be detected through in vitro testing.(13)  
Antimalarial resistance threatens the success of malaria treatment programs.  
Effective treatment of malaria is also complicated by the biological, geographic, and 
therapeutic interactions between malaria and Human Immunodeficiency Virus (HIV) 
which will discussed in greater detail in following sections.   
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 This dissertation examined factors relevant to malaria treatment in two distinct 
frameworks.  The first aim was to explore the impact of misclassification on cure 
rates in antimalarial efficacy studies using simulations and to develop a Monte Carlo 
uncertainty analysis.  The second aim was to quantify the effect of a co-formulation 
of two HIV-1 protease inhibitors (PIs), lopinavir (LPV) and ritonavir (RTV), on 
malaria incidence using a discrete-time survival analysis. 
A.  Factors influencing PCR-corrected cure rates in antimalarial efficacy trials 
The World Health Organization (WHO) recommends that first-line antimalarial 
treatment policies be changed when a drug’s cure rate falls below 90%.(14) The cure rate 
is the proportion of patients who recover and become aparasitemic after receiving 
treatment.  To estimate that proportion, differentiating between reinfection and 
recrudescent infection is essential.  Polymerase chain reaction (PCR)-correction of cure 
rates, that is, genotyping paired samples from patients before and after treatment to 
classify whether recurrent parasitemia is a new infection or reflects treatment failure, has 
been in use for more than 20 years.  However, PCR-correction may produce erroneous 
results dependent upon the diversity of genetic markers in the local parasite population, 
the allelic frequency of those markers, and transmission intensity.  The insensitivity of 
PCR to minority variants may also lead to misclassification.  
 
1. Classification of recurrent parasitemia 
a. PCR-correction 
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 PCR involves the use of primers (sequences of DNA that are complementary to 
regions of the genetic marker of interest), nucleotides and a DNA polymerase to amplify 
segments of DNA to observable quantities; it allows researchers to determine which 
genetic variants are present in a biological sample.  PCR-correction, the use of 
genotyping to distinguish between reinfection and recrudescent infection, is used to 
adjust cure rates (“cure rate” is commonly used in the literature and is the language we 
use here for consistency, however it is actually the proportion of patients who are treated 
successfully) in antimalarial efficacy studies.  By comparing parasite variants present in 
the patient before and after treatment, researchers can decide if the patient cleared the 
initial infection and has become reinfected, or if she has not cleared her initial infection 
(recrudescence).   
In a recent review, it was reported that the first use of PCR-correction was in 1997 
and it has become increasingly common.(15) One of the earlier assessments of PCR-
correction declared that to be successful in differentiating between reinfection and 
recrudescence, “the theoretical requirements would be: (1) ensured protection from 
additional mosquito bites; (2) coadministration of drugs effective against liver stages, 
such as primaquine; and (3) analysis of a sufficient number of consecutive samples.”(16) 
In the absence of such an ideal setting, the authors suggested that adequately reliable 
results can be achieved with sufficient sampling, PCR efficiency, and sufficient 
resolution to identify different alleles.(16)  
 The importance of PCR-correction is well-documented and understood.  In a 
review of antimalarial studies conducted from 1995 to 2005, 175 treatment arms were 
identified in which PCR-correction had been used.  In 41 treatment arms (26%), new 
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infections were responsible for 50-74% of recurrent infections.  In 36 treatment arms 
(23%), new infections were responsible for at least 75% of recurrent infections.(15)  In 
another evaluation of data from multiple studies, the authors concluded, “Without PCR 
genotyping, 36% of the recurrent parasitemias after day 14 (260/696 recurrences) would 
have been wrongly classified as failures.  This would have lead to 1,048 cases being 
considered failures by day 28 (352 by or before day 14 plus 696 between days 14 and 
28), thus overestimating the risk of failure by about one-third.”(17) Differences between 
crude and PCR-corrected failure rates greater than 10% have been reported 
elsewhere.(18)  Not all studies have found that many episodes of recurrent parasitemia 
were the result of reinfection; one study found that all recurrent parasitemias were the 
result of recrudescence though in that study all 12 participants carried isolates resistant to 
both treatments. (19)  
PCR-correction is not without limitation and misclassification of both reinfections 
and recrudescent infections can occur.  It is possible that a new infection will be of the 
same variant as the first and the recurrent parasitemia will erroneously be classified as a 
recrudescent infection.  Conversely, PCR may fail to identify all the genotypes in the pre-
treatment sample and the recurrent parasitemia may be falsely classified as a new 
infection.  Factors that play a role in these types of misclassification will be discussed in 
greater detail below.  
 b. Definitions of recrudescence  
 Different definitions of recrudescence appear in the literature; this changes 
analytical approaches with regard to how and which patients are considered when 
calculating the cure rate or other endpoint.  The WHO recommends that markers sharing 
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even a single band indicate recrudescence but if any of the markers genotyped do not 
share a band, indicating a new infection, then that is the patient’s classification.(20) Other 
definitions attempt a more nuanced approach.  Kwiek et al. considered recurrent 
parasitemias that shared a single, highly prevalent band (appeared in more than 10% of 
samples) indeterminate, not recrudescent.(21)  For indeterminate parasitemias, they used 
the frequency of the shared allele and the number of variants in recurrent samples to 
calculate an estimated probability of a chance-match.(21)  Cattamanchi et al., who had 
genotyped msp1 (the gene encoding merozoite surface protein 1) , msp2 (the gene 
encoding merozoite surface protein 2), and glurp (the gene encoding glutamate rich 
protein), explored different ways of addressing “indeterminate” recurrences, those in 
which the patient had both shared and new alleles.(22)  They considered three schemes: 
(1) all recurrences classified as recrudescent, (2) recurrent infections classified as 
reinfections if at least 50% of the post-treatment bands were new, or (3) all recurrences 
classified as reinfections. They found that using the second scheme generated hazard 
ratios most similar to their reference group (patients who had only shared or only new 
bands) and concluded, “Our analysis showed that the episodes initially classified as 
indeterminate were much more likely to be caused by reinfection than by 
recrudescence.”(22)   
Additionally, which samples are even subject to genotyping varies.  In a review 
by Collins et al. they found that, “Most trials only genotyped samples from episodes of 
recurrent parasitemia that occurred after a defined number of days following 
therapy.”(15) It is not uncommon for patients who fail within the first seven or even 14 
days after treatment to automatically be considered recrudescent.(17, 18, 22) This may be 
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unwise as unexpectedly high numbers of new infections among recurrent parasitemias 
have been identified as early as Day 7 (19%) and Day 14 (47.1%).(23)  Of course, these 
high numbers may also be the result of PCR-related misclassification of recrudescent 
infections. 
c. WHO and Medicines for Malaria Venture (MMV) recommendations 
 The WHO recommends that antimalarial efficacy trials follow patients for no 
fewer than 28 days and that PCR-correction be used to differentiate reinfection from 
recrudescence.(20) In 2007, recommendations for standardizing PCR-correction were 
issued by a collaboration of the WHO and MMV(20); they included: 
1. Definition of a new infection: Recurrent parasitemia “in which all alleles in the 
post-treatment sample…are completely different from those in the admission 
sample,” for at least one loci (Figure 2). 
2. Definition of a recrudescent infection: At each locus, one or more alleles are 
shared in pre- and post-treatment samples (Figure 2). 
 
 
Figure 2. WHO/MMV definitions of recrudescence and reinfection.  Used with 
permission.(20) 
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3. Only two samples are required (no consecutive sampling), one pre-treatment and 
one at the time of recurrent parasitemia. 
4. Use of commercial blood collection cards as opposed to untreated filter paper 
(this helps to ensure the success of genotyping).   
5. Use of capillary electrophoresis when possible (this increases the ability to 
distinguish between different alleles). 
6. Stepwise (stopping when a new infection is detected) nested PCR genotyping of 
all recurrent parasitemias for msp1, msp2, and glurp (Figure 3). 
7. Accreditation of laboratories to provide quality assurance. 
8. When the PCR-corrected cure rate falls below 90%, they recommend collecting 
and reporting additional information: existence of gametocytes at the time of 
recurrent parasitemia, the average multiplicity of infection and the distribution of 
alleles in the parasite population.  They state that these values can then be used to 
calculate chance-matches but do not make a specific recommendation for how to 
do this. 
      These recommendations are useful with regard to standardization, an important 
next step when considering the wide variety of genotyping techniques and definitions of 
recurrence, a shortcoming highlighted by Collins et al.(15)  However, the 
recommendations do not address all of the technical and biological factors that affect 
PCR-correction.  These factors are discussed below. 
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Figure 3. Stepwise genotyping with three markers.  Used with permission. (20) 
  
2. Technical considerations of PCR-correction 
a. Selection of genetic markers 
Frequently used markers for PCR-correction include msp1, msp2 and glurp.  They 
are considered useful because they: (A) contain variable regions that result in different 
sizes of PCR products, (B) tend to have high diversity within parasite populations, (C) 
and are single-copy genes on different chromosomes.    
Microsatellites, non-coding repeated sequences of nucleotides, have been 
suggested as alternatives to traditional markers.  The argument for their use includes the 
possibility that msp-coding genes and glurp may be under immune selective pressure.(10) 
In a study of microsatellite use, researchers compared analysis of a single polymorphic 
microsatellite to analyses of msp1 and msp2.  They found that the detection threshold was 
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similar to that of msp1 and an order of magnitude lower than msp2.  From a total of 69 
samples, 46 (67%) had been classified as recrudescent by using a combination msp1 and 
msp2; when the samples were then evaluated for the microsatellite, 23 of those 46 
samples (50%) appeared to be new infections.  Seven of 30 samples (23%) identified as 
recrudescent by microsatellite analysis were new infections according to analysis by the 
msp genes.(10)  
In addition to which markers are used, the number of markers must be decided 
upon.  Though an analysis of multiple studies found that, “use of at least three genotyping 
markers was not found to increase the odds of classification as new infection...”, (15) 
many have argued for the use of multiple markers.  This is primarily due to the increased 
allelic diversity afforded by multiple markers which may be especially important in low 
transmission areas where parasite diversity is thought to be low.(22)  The benefits of 
multiple markers need to be balanced against cost and the likelihood of results that are 
difficult to interpret.(22)  Additionally, the use of multiple markers increases the 
probability that at one locus PCR will fail to detect all pre-treatment genotypes possibly 
leading to misclassification of a true recrudescent infection.(5)  A stepwise approach to 
genotyping in which no additional markers are evaluated after one identifies a new 
infection has been used and is recommended by the WHO and MMV.(20)  
b. Consecutive-day sampling 
 Using a single pre-treatment and single post-treatment sample may result in an 
incomplete description of a patient’s infection resulting in outcome misclassification if 
within-host parasite population dynamics are highly changeable as they are in 
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asymptomatic patients.(24)  Whether population dynamics are similar in symptomatic 
patients has been the subject of some debate.   
 In a study of 13 cases of malaria who returned to Sweden after travel in malaria-
endemic areas and had blood samples taken at 12 hour intervals for a minimum of three 
days during and after treatment, 12 (92%) had the same genotypes in all samples (in some 
patients, the post-treatment samples had only a subset of the pre-treatment 
genotypes).(25)  This indicated that multiple samples may be less necessary in 
symptomatic patients when determining their parasite populations.  However, the authors 
did allow that, “follow-up analysis in drug trials distinguishing recrudescent parasites 
from new infections may still be favored by analysis of additional samples…since an 
asymptomatic parasitemia may confer dynamics other than the infection in the acute 
phase and a single sample may then only partly reflect the infection parasite 
population.”(25) In another study in which samples were drawn on Day 0 – 3, 7, 14, 21, 
28, 35, 42 and any day of recurring illness, standard single sample analysis performed 
similarly well to repeated sampling, identifying 27 of 33 recrudescences (82%) when 
genotyping msp2 and 17 of 21 (81%) when genotyping both msp1 and msp2.(26) 
However these authors also chose to recommend more than one pre- and post-treatment 
sample, suggesting instead that samples be taken on two consecutive days at the 
beginning of follow-up and on two consecutive days at the time of recurrent 
parasitemia.(26) Stronger support for the use of multiple samples came from a study that 
used a quantitative fragment-analysis, as opposed to standard PCR methods.  They found 
that parasite populations within symptomatic patients were highly changeable; 14 of 20 
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patients (70%) had clones that “showed major fluctuations,” with some clones 
disappearing and reappearing within two hours.(27)  
c. Sensitivity and resolution 
 Differentiating between two alleles is a requirement of distinguishing between 
reinfection and recrudescence.  The WHO/MMV genotyping recommendations provide 
guidance on the extraction of DNA and storage of samples (20); these issues certainly 
play an important role in the efficiency and sensitivity of PCR-correction.  For the 
purposes of this project, other factors affecting the identification of distinct alleles, 
namely PCR sensitivity and resolution of amplification products, are of greater interest. 
 Nested PCR (nPCR) which uses two rounds of amplification, thereby reducing 
non-specific amplification, is recommended by the WHO/MMV for genotyping and is a 
technique found frequently in the literature.  However it has at least two important 
limitations.  First, it only can detect differences in allelic size, not sequence.  Second, 
amplification products are frequently run on agarose gels; it is widely understood that it is 
impossible to resolve small differences in the position of bands on such a gel.  In 
appreciation of this, researchers have to decide how to “bin” the results which will 
determine how close two bands must be in size to be considered a match.  Greenhouse et 
al. chose a bin width of 20 base pairs (bp) for the results of their msp1 and msp2 analysis 
(this means that bands within a 20bp range were considered matches)(5); Brockman et al. 
used 40bp bins for msp1 and msp2 and 60bp bins for glurp.(28)  
 Heteroduplex tracking assays (HTAs), which use radiolabeled probes to bind to 
host amplicons, are more sensitive to size differences than PCR and are able to detect 
insertions, deletions, and clustered base-pair mismatches.(21, 29) Additionally, PCR 
 15 
 
appears unable to detect minority populations of parasites, those that make-up less than 
10 to 20% of the total within-host population.(30, 31)  Using HTAs, one study found that 
five of six new infections (83%) identified by PCR-correction were actually true 
recrudescences.(29)  This was likely the result of PCR insensitivity to minority 
variants.(29)  Because HTAs use radioactive probes they are not available for use in 
much of the developing world, however a new HTA that uses a non-radioactive, 
chemiluminescent probe appears effective.(32)  The insensitivity of PCR to minority 
variants is troubling; when minority variants in the pre-treatment sample are not detected 
it can lead to misclassification of recrudescent infections which artificially inflates 
estimates of drug efficacy. 
 
3. Biological factors that complicate PCR-correction 
a. Gametocytes 
 Gametocytes are the sexual stage of malaria parasites and do not replicate or 
cause disease within a human host.  They circulate in the peripheral blood and are 
ingested by mosquitoes during feeding resulting in parasite transmission.  Gametocytes 
are not susceptible to many antimalarial drugs and have a longer life then other stages of 
the parasite, living up to 22 days.(2)   This is concerning in the context of PCR-correction 
because they may remain circulating after successful treatment, erroneously reflecting 
recrudescent parasitemia.  Traditional PCR can detect all parasite stages; gametocytes can 
only be identified differentially using reverse transcriptase-PCR to detect messenger 
RNA of genes only expressed during this stage.  This technique is not widely available 
and misclassification may occur as a result.  Some reassuring evidence was provided by a 
 16 
 
study from Uganda that found only 16 of 371 paired samples (4%) had gametocytes, 
however the methodology they used to identify gametocytes was not reported.(22)  
 b. Sequestration and synchronicity 
Sequestration of parasites and synchronicity may also affect which parasite 
variants are circulating at detectable levels in the peripheral blood, in turn resulting in 
incorrect interpretation of genotyping results.  In synchronous infections where 
erythrocytes burst, releasing thousands of merozoite-stage parasites at the same time, 
parasite densities potentially fluctuate enough to fall below detectable levels.(16) 
Conversely, asynchronous infections also complicate the interpretation of findings.  
Snounou and Beck drew attention to this, “many P. falciparum infections are relatively 
asynchronous: the paroxysms can occur at any time, and two or more can be recorded in 
quick succession, reflecting an intricate dynamic pattern for the growth of different 
parasite broods.”(16) Snounou et al. also discuss the potentially misleading role of 
sequestration of parasites stating that, “late erythrocytic parasite stages are sequestered in 
the deep vasculature and therefore might not be present in a peripheral sample.”(16) 
Appreciating the potential role of these factors is important although assessing their true 
impact or adjusting for them in the analysis is beyond the scope of this project. 
 c. Distribution of alleles in the parasite population 
 The distribution of alleles in the parasite population impacts the likelihood of 
observing matching bands in pre- and post-treatment samples.  Numerous authors have 
emphasized that allelic diversity must be high enough to sufficiently reduce the 
probability that a new infection matches the initial infection by chance.(5, 16, 17, 21, 28, 
33) Greenhouse et al. used frequency distributions to calculate the probability of a 
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chance-match (homozygosity) and found values ranging from 0.047 (msp2) to 0.18 
(TA81, a microsatellite); an increase in allelic diversity reduces homozygosity.(5)  
 
4.  Adjustment of PCR-correction through the use of probability theory 
 PCR-correction is a useful and important tool, though clearly not without 
limitation.  Though impossible to simultaneously address each factor potentially affecting 
the accuracy of PCR-correction, generating one perfect estimate that truly quantifies drug 
efficacy, adjustments made based on the allelic distributions of the local parasite 
population seem an appropriate first step; “In order to optimize the use of PCR 
genotyping, it is important to calculate the pretest probability of the same genotype 
occurring in the same individual pre- and posttreatment.”(17) These adjustments use 
probability theory to calculate the probability of a chance-match, i.e. the likelihood of a 
reinfection matching the pre-treatment sample genotype simply by coincidence.(5, 21, 28, 
33)  It has been emphasized that patients with multiple infections have a higher 
probability of a chance-match.(5)  The techniques discussed below are a means to adjust 
for misclassification of new infections; it should be noted that they cannot address 
misclassification in the other direction (erroneously classifying a recrudescent infection 
as a new infection because of PCR insensitivity). 
Greenhouse et al. used a probability-based approach to help answer two 
questions, (1) how many markers are needed to accurately classify recurrent infections, 
and (2) how does transmission intensity affect genotyping results?(5)  They genotyped 
600 pre-treatment and post-treatment samples using msp2, msp1, and four microsatellites; 
they also used the pre-treatment samples to generate allele frequency distributions for 
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each marker.  Treating the frequency distributions as probability distributions, they 
calculated the probability that a pre- and post-treatment allele matched by chance (Pmatch) 
for each study participant in an area of low to moderate transmission and in a high 
transmission site.  They then adjusted the number of recrudescent infections in each 
treatment arm separately, as determined by PCR-correction, by the average Pmatch (a 
thorough description of their approach and their formulas are in Appendix B).  They also 
evaluated the effect of using multiple markers by multiplying the average Pmatch for each 
marker together to calculate an “overall” Pmatch and adjusted the PCR-corrected results 
using that value.  Their findings confirmed anticipated results: higher allelic diversity 
conferred a lower Pmatch and higher multiplicity of infection increased Pmatch.  The site 
with lower transmission intensity reached a very low overall Pmatch (0.02) within three 
markers, whereas the higher transmission site never reached a particularly low Pmatch 
value even with all six markers (0.16).  The authors concluded that in the lower 
transmission area, “treatment estimates adjusted by genotyping estimates became similar 
to those adjusted by both genotyping and chance matches… In [the high transmission 
site], however, the risk estimates remained dissimilar even after genotyping with all six 
markers...  This suggests that even genotyping with the six markers described in this 
report may substantially overestimate the true risk of treatment failure at very high 
transmission sites.”(5)  Overestimating drug failure could result in rejection of a 
potentially useful compound during drug development.   
Kwiek et al. evaluated all patients with recurrent parasitemias and calculated how 
closely they matched (the number of shared bands) and how prevalent the matching 
alleles were in the parasite population.(21)  They considered recurrent parasitemias 
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sharing a single band that appeared in more than 10% of samples indeterminate (neither a 
new infection or recrudescence).  For indeterminate parasitemias, they then used the 
prevalence of the shared allele and the number of variants in the recurrent sample to 
calculate an estimated probability of a chance-match.  They multiplied the mean 
probability of treatment failure (1 – the mean of the chance-match probabilities) by the 
number of indeterminate infections and adjusted the proportion of treatment failures 
accordingly (Formula in Appendix C).  Like Greenhouse et al., they concluded that 
probability-based adjustments of genotype-corrected rates (they used HTAs, not PCR) 
may be useful in high transmission areas.(21)  
Not all researchers agree that chance-matches play an important role.(18, 23)  
However, the findings of studies that used probability-based adjustments of genotyped 
results(5, 21, 28, 33) strongly indicate that this is incorrect.   
 
5.  Uncertainty analyses 
 Traditional estimation of confidence intervals accounts only for random error.  
Bayesian methods can be used to incorporate prior information on biases and other 
methods have also been developed.(34-37)  An analysis presented by Jurek et al. 
corrected for outcome misclassification using a Monte Carlo analysis instead of a 
Bayesian analysis.  They argued this was sufficient because they were not specifying a 
prior distribution of the parameter of interest itself, only prior distributions related to the 
misclassification.(36)  Though their subject area was not infectious diseases, 
modifications to their approach would make it relevant to outcome misclassification in 
antimalarial efficacy trials. 
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In conclusion, PCR-correction is a useful first step in estimating treatment 
efficacy, but without the incorporation of additional information, such as the distribution 
of genetic variants in the parasite population and multiplicity of infection, it can result in 
misclassification of a patient’s outcome.  The ability of PCR-correction to correctly 
classify a patient’s outcome is also limited by the insensitivity of PCR to minority 
variants.  The use of probability-based adjustments, can take these factors into account, 
could potentially play an important role in generating more reliable estimates of cure 
rates. 
 
B.  The effect of HIV-1 protease inhibitors on incidence of malaria 
Protease inhibitors are not currently recommended for use as first-line ART in 
Sub-Saharan Africa.(38) However, the recent advent of a heat stable co-formulation of 
two PIs, lopinavir and ritonavir (LPV/r), coupled with the demonstrated resistance to 
first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy(39) 
makes it likely the use of PIs will increase.  Furthermore, laboratory evidence has shown 
that LPV/r and other HIV PIs inhibit the growth of P. falciparum; if this is found to also 
be true in humans, the use of HIV PIs in malaria-endemic parts of the world would be 
even more valuable.  
 The Adult AIDS Clinical Trials Group (AACTG) conducted a study 
comprising two phase III randomized clinical trials (RCT): one for HIV-1-infected, 
treatment-naïve women and one for HIV-1-infected women who have been exposed 
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to single-dose nevirapine (NVP) to prevent mother-to-child transmission of HIV-1.  
In each RCT there were two treatment arms; one in which patients received NNRTI-
based therapy, the other in which patients received protease inhibitor LPV/r-based 
therapy.(40)  We conducted an ancillary study using data collected by the AACTG 
trials to look at the effect of LPV/r on P. falciparum infection in adults. 
 
1.  Malaria and HIV-1 
The geographical overlap of malaria and HIV is striking.  It is estimated that 
almost one million people die of malaria every year; most of whom live in Sub-Saharan 
Africa.(1)  The Joint United Nations Programme on HIV/AIDS reported that roughly 
22.5 million people were living with HIV/AIDS in Sub-Saharan Africa in 2007; a far 
greater number than any other region of the world.(41)  
The biological interaction between HIV-1 and malaria is well documented (all 
references to HIV for the remainder of the document refer to HIV-1).  The reciprocal 
nature of the interaction – HIV increases malaria incidence and worsens clinical 
manifestations, malaria elevates HIV viral load – makes it crucial to understand its 
repercussions in an effort to improve prevention and treatment strategies.  Using a 
mathematical model, Abu-Raddad et al. estimated that in an adult population of 
approximately 200,000, and in an area in which both HIV and malaria are highly 
prevalent and malaria interventions not used, between 1980 and 2006 the interaction may 
have led to more than 8,000 excess cases of HIV and almost one million excess cases of 
malaria.(42)  
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a. The effect of HIV on malaria 
HIV is associated with increased parasitemia, clinical malaria and severe malaria.  
In 2000, Whitworth et al. described the role of HIV on parasitemia and episodes of 
clinical malaria.(43)  Based in a malaria-endemic region of Uganda, the study followed a 
cohort of 484 adults from 1990-1998 and conducted both scheduled and interim visits 
when participants felt ill.  HIV was associated with increased odds of both parasitemia 
and clinical malaria (Table 1).  Among HIV-infected individuals, those with lower CD4 
counts tended to have higher parasite burdens.(43)  
 
Table 1. Malaria status among study participants at routinely scheduled visits 
HIV status Parasitemia 
N/total (%) 
Odds ratio  
(95% CI)* 
Clinical Malaria 
N/total (%) 
Odds ratio  
(95% CI)* 
     
   Negative 231/3688 (6.3) - 26/3688 (0.7) - 
   Positive 328/2788 (11.8) 1.81 (1.43, 2.29) 55/2788 (2.0) 2.56 (1.53, 4.29) 
     
Data taken from Whitworth et al.(43)    *Odds ratios adjusted for age, sex and pregnancy 
 
Patnaik et al. evaluated the effect of HIV serostatus, viral load, and CD4 counts 
on parasitemia. They calculated hazard ratios (HR) and found that first-episode, second-
episode and overall incidence of parasitemia were all greater in HIV-infected adult study 
participants who were followed for a single rainy season in Malawi, a malaria-endemic 
country.(44) They found an increased rate of first-episode parasitemia associated with 
increased HIV RNA concentration (Adjusted HR (95% CI) per 1-log increase = 1.24 
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(1.02, 1.51)) and of second-episode parasitemia (Adjusted HR (95% CI) per 1-log 
increase = 2.12 (1.14, 3.92)). The direction of this association was the same when 
considering overall incidence of parasitemia though not statistically significant (Adjusted 
HR (95% CI) per 1-log increase = 1.24 (1.02, 1.51)). (It is of note that when assessing the 
effect of HIV RNA concentration they did not adjust for CD4 count.)  The hazard of a 
first-episode of malaria was lowest among individuals with ≥ 400 CD4 cells/µl.(44)  
 Clinical malaria is also associated with HIV and its resulting immunosuppression.  
Evidence suggests that there is an increased relative risk of clinical malaria among 
individuals with fewer CD4 cells and more advanced HIV disease.(43)  In a cohort of 
HIV-infected adults in Uganda, the rate of malarial febrile episodes among individuals 
with fewer than 200 CD4 cells/µl was more than twice that of the rate among individuals 
with > 500 CD4 cells/µl (139.8/1000 person-years compared to 57.3/1000 person-
years).(45)  
Grimwade et al. conducted a study in an area of unstable malaria transmission to 
observe the effect of co-infection among a population with lower levels of the partial-
immunity one would expect to find in endemic regions.(46) They reported a significant 
association between HIV and severe malaria disease among adults with confirmed 
malaria [Adjusted Odds Ratio (OR) (95% CI) 2.3(1.4, 3.9)].(46)   
In summary, HIV has been linked to increased parasitemia, clinical malaria, and 
the severity of malaria disease among adults.  This association is found in both endemic 
areas and areas of unstable transmission. 
 
b. The effect of malaria on HIV 
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Malaria also exacerbates HIV infection.  Kublin et al. conducted a prospective 
cohort study that followed HIV-infected patients at regularly scheduled and interim visits 
when participants experienced illness.(47) They measured the amount of HIV RNA at 
baseline, at the time a patient was found to be parasitemic and, on average, 8-9 weeks 
post-malaria.  They found that concentration of viral RNA, for patients with baseline 
CD4 >300/µl, nearly doubled during the episode of malaria; this effect was even stronger 
among patients with high levels of parasitemia (≥2000/µl) and fever.  They observed no 
significant difference in HIV RNA levels over time for participants who did not 
experience an episode of parasitemia.(47)  In another cohort of HIV-infected individuals, 
patients with clinical malaria had a median viral load almost seven times that of non-
parasitemic controls.(48)  Though the effect of high viral load may in fact have made the 
patient more susceptible to malaria (thereby confusing this effect), there was a 
progressive decline of median viral load after treatment for malaria and after four weeks 
there was no significant difference in median viral load between individuals recovering 
from malaria and the control group.(48) The mechanism by which malaria increases viral 
load is still under study; some evidence suggests it may be related to increased production 
of TNF-α.(49, 50)  
 Malaria is also associated with a decline in CD4 cells.(51) After adjusting for 
baseline variables, including baseline CD4 count, Mermin et al. reported that the average 
decline in CD4 cells was, per episode of malaria, 40.5/µl.  When compared to HIV-
infected individuals who experienced no episodes of malaria, people who had at least 
three episodes experienced an annual decrease in CD4 cells of more than 140/µl.(51)  
2.  The treatment of HIV-1 in Sub-Saharan Africa 
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 In the 2006 antiretroviral treatment (ART) guidelines for resource-poor countries 
issued by the WHO, a combination of three drugs was recommended: two nucleoside 
reverse transcriptase inhibitors (NRTI) and a single NNRTI (either efavirenz (EFV) or 
NVP).(52) NVP is less expensive than EFV and is widely used, however its use carries 
with it risk of severe rash and rarely hepatotoxicity.(52)    
The 2009 revisions to the WHO guidelines do not recommend PI-based therapy as 
a first-line treatment, only a second-line treatment.(38)  However the new availability of 
heat stable LPV/r in combination with observation that resistance to the complete class of 
NNRTI therapies can result from a single nucleotide polymorphism in HIV-1(52) makes 
reassessment of PI-based therapy important.  One aim of the AACTG study was to 
investigate the possibility that NNRTI-based ART is less effective in patients with 
previous NNRTI exposure (in the form of single-dose NVP) due to the selection of 
resistant virus resulting from that exposure.  This possibility makes the option of using 
PI-based therapy as a first-line treatment attractive and worthy of further consideration.  
Second line therapy use in the developing world is also increasing over time and is 
almost exclusively PI-based.   
       
3.  Diagnosis and treatment of co-infected individuals 
There are risks associated with concurrent use of antimalarials and 
antiretrovirals.(53, 54) Brentlinger et al. reviewed the diagnostic and treatment 
challenges resulting from the overlap of the two infections, highlighting the need for 
medications effective against both diseases.(53)  They proposed five reasons why “the 
HIV-infected patient residing where malaria is endemic or epidemic may be at risk of 
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misdiagnosis and mismanagement…” In summary they are: 1) symptoms of both 
conditions can be varied  “[making] clinical decision making…difficult”; 2) malaria may 
occur simulatneously with other infections or even adverse reactions to ART, causing 
difficulties for patient management; 3) a possible increase in unneeded malaria treatment 
in patients with fever, or alternatively failing to diagnosis malaria in a patient with 
symptoms associated with HIV or adverse reactions to ART; 4) insufficient information 
available for evidence-based concomitant treatment of both infections; and, 5) lack of 
clinical facilities to correctly diagnose malaria. The “overlapping adverse effect profiles” 
of certain antiretroviral and antimalarial drugs, and the known deliterious drug 
interactions between the two types of treatments(53), make the possability of a 
medication that can treat both diseases highly desirable. 
There are drugs used as chemoprophylaxis in HIV-infected patients that protect 
them from malaria.  For example, co-trimoxazole use in HIV-infected patients reduces 
incidence of malaria.(55).  Though co-trimoxazole reduces morbidity and mortality 
among those infected with HIV, it is does not treat or cure HIV.   
 
4.  Antimalarial action of protease inhibitors  
 The antimalarial properties of PIs were first demonstrated in laboratory studies 
more than a decade ago.  In Rosenthal’s 1995 article in Experimental Parasitology, he 
reported the deleterious effect of PIs on the malaria parasite.(56) Malaria parasites 
construct proteins by hydrolyzing the host erythrocyte’s hemoglobin and using the 
resulting amino acids.(57) Rosenthal cultured parasites with different chemical agents 
and found that cysteine PIs caused morphological changes in the food vacuole of the 
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parasite.(56) Aspartic PIs did not cause such an abnormality but were also toxic to the 
parasite.(56) This in vitro evidence warrented further investigation into the antimalarial 
nature of PIs. 
Experimental approaches to quantifying antimalarial effects relevant to this 
dissertation have primarily involved incubating cultured parasites, of various antimalarial 
drug sensitivities, with HIV PIs and measuring growth inhibition.  Skinner-Adams et al. 
published the “first report that antiretroviral PIs can directly inhibit in vitro growth of 
both drug-sensitive and drug-resistant P. falciparum parasites.”(58)  The observed 
efficacy against drug-resistant parasites is particularly important in the context of 
growing antimalarial drug-resistance.  Several agents were particularly harmful to the 
growth of the parasite including RTV, a component of LPV/r, whereas NVP had no 
effect.(58)  Growth inhibition resulting from exposure to concentrations of LPV (0.9-
2.1µM) which are lower than those found in the plasma of a  patient on LPV/r ART have 
also been described.(59)  It is of note, however, that LPV/r is 98-99% protein bound(60); 
this may indicate that the in vitro concentrations resulting in parasite growth inhibition 
may be higher than those freely available in a patient.  Parasites exposed to LPV alone, 
RTV alone, or LPV/r experienced growth inhibition and exposure to RTV alone resulted 
in morphological changes of the parasites.(61)  In an ex vivo experiment, parasites 
exposed to sera taken from HIV-infected patients taking LPV/r had a 50-95% reduction 
in growth when compared to serum from controls.(62)   
Andrews et al. provided the first evidence of an in vivo effect of LPV/r.(61)  They 
compared the efficacy of multiple chemotherapeutic agents against the non-lethal murine 
model of malaria, P. chabaudi.  LPV/r decreased the median peak parasitemia and 
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delayed onset of parasitemia by two days (compared to the control).(61) Evidence from a 
different murine model, P. yoelii suggested that HIV PIs, including LPV, also 
demonstrate action against pre-erythrocytic stage parasites.(63) 
 The mechanism for the observed antimalarial effect of HIV PIs is still unknown;  
initially it was believed that the agents interfered with plasmepsins I-IV (four of the ten 
P. falciparum aspartyl proteases) which function within the food vacuole.(58)     
Additional evidence bolstered this hypothesis: structural similarities between plasmepsin 
II and the HIV protease,(64) docking studies that suggested bonding interactions between 
HIV PIs and plasmepsins II and IV are possible,(61) and by measuring the inhibition of a 
“hemoglobin-based peptide substrate by recombinant plasmepsin II,” it was found that 
plasmepsin II was inhibited by LPV and RTV in vitro.(59)  
 New evidence, however, suggests that the antimalarial effect of HIV PIs may not 
be related to food vacuole plasmepsins.  In both drug interaction studies and experiments 
with knockout parasites, Parikh et al. concluded that HIV PIs do not act in the same way 
as pepstatin, an aspartic protease inhibitor known to have antimalarial action.(65) 
Experiments that measure the interaction of HIV PIs and chloroquine also support a non-
food vacuole mechanism of action.  The antimalarial action of chloroquine is not fully 
understood but it is believed to act on heme, the iron-containing prosthetic group of 
hemoglobin, after it is cleaved from the hemoglobin molecule by the food vacuole 
plasmepsins.(66)  Synergism between HIV PIs and chloroquine would therefore be 
unexpected if HIV PIs inhibit food vacuole plasmepsins.  However, synergism does 
occur.(67, 68)  Additionally, RTV and saquinavir (another HIV PI), suppress growth of 
P. vivax.(69)  P. vivax has only a single ortholog to a P. falciparum food vacuole 
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plasmepsin(70), and that ortholog is not transcribed during the ring stage, suggesting that 
the food vacuole plasmepsins are not the target of HIV PIs.(69)    Recent experiments 
that explored antimalarial activity throughout the parasite’s within-human life cycle, 
found that HIV PIs were responsible for the strongest growth inhibition during the 
trophozoite and schizont stages and also acted on gametocytes, leading the researchers to 
cautiously conclude, “that the primary target of the PIs is likely to be expressed in both 
gametocytes and intra-erythrocytic parasites…plasmepsins V, IX, and X appear to be the 
best candidate targets of these drugs.”(71)  
Nathoo et al. proposed that HIV PIs may have a beneficial consequence for 
patients with malaria independent of antiparasitic effects.(72) In vitro, they found a 
marked reduction in the expression of CD36, a human surface receptor associated with 
the binding of malaria parasites, after exposure to several ART compounds, including 
RTV.  They observed that the “induced CD36 deficiency [results] in decreased CD36-
mediated cytoadherence…of parasitised erythrocytes.”  The authors did, however, 
caution that decreased expression of CD36 could also potentially harm the patient, 
postulating that parasites may then simply bind to another surface receptor, ICAM-1, 
which is implicated in cerebral malaria.  Additionally, the decrease in CD36 also reduced 
phagocytosis of parasitized erythrocytes which may reduce the patient’s ability to fight 
the infection.(72)  
In conclusion, though laboratory evidence supports the antimalarial effect of HIV 
PIs on malaria parasites, the mechanism for that action remains unknown.  Additionally, 
HIV PIs may reduce the parasite’s ability to bind to host cells though the repercussions of 
this effect are not understood.  Currently there is nothing known about an antimalarial 
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effect of HIV PIs in humans.  Data from the AACTG trials provide the first opportunity 
to examine incidence of malaria among HIV-infected individuals on PI-based therapy.      
 
 
  
 
CHAPTER 2 
RESEARCH DESIGN AND METHODS 
 
A. Factors influencing PCR-corrected cure rates in antimalarial efficacy trials 
This aim had two objectives.  First, to demonstrate the effect of the distribution of 
allelic variants, transmission intensity and MOI on the probability of misclassification of 
recurrent infections.  Second, to develop a practical approach for adjusting PCR-
corrected results for misclassification of both reinfections and recrudescences, and 
provide a worked example using data from areas of both high and low transmission 
intensity.   
 
1. Characteristics affecting the probability of false positives 
We used simulations of the infection, cure, and re-infection process to 
demonstrate the effect of allelic diversity, transmission intensity and MOI on the 
probability of a false positive.  In this context, a false positive refers to a reinfection that 
is misclassified as a recrudescence because allelic variants in the day 0 and day R 
samples match by chance.  We used MATLAB R2008a (Natick, MA) software to 
simulate infections (and re-infections) of individual patients after specifying the 
population-wide distribution of allelic variants.  The parameters of these distributions 
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were based on values in the literature on relevant P. falciparum genetic markers.  For 
each of 100,000 simulated patients, we assigned a specified number of day 0 variants 
drawn randomly from the distribution.  We set treatment success at 100% and assigned a 
specified number of day R variants the same way.  We tested all patients for matching 
day 0 and day R variants, and calculated the probability of a false positive as the number 
of patients with a match divided by 100,000, the number of simulated patients.   
We first assessed the effect of allelic diversity in the parasite population on the 
probability of a false positive.  As in routine PCR-correction, allelic variants were 
distinguished by the number of base pairs (bp); due to the insensitivity of nPCR to small 
variations in the number of bp, variants that were different by no more than 20bp were 
considered to be the same to replicate the degree of precision routinely allowed.  We used 
allelic distributions appearing in the literature to inform a plausible mean, 350bp, and a 
wide range of variances, from 1575 to 6475, to generate ten negative binomial 
distributions.  The negative binomial distribution is believed to most accurately represent 
allelic distributions within parasite populations.(73)  For each distribution, we simulated 
the infection and reinfection of 100,000 patients by assigning each a single day 0 variant 
and a single day R variant drawn randomly from the distribution.   
 We assessed the effect of transmission intensity on the probability of a false 
positive by assigning each patient one day 0 variant and one, two, three or four day R 
variants, each reflecting an infectious bite (for simplicity, we assumed each infectious 
bite transmitted a single variant).  We simulated the effect of MOI similarly, assigning 
each patient one through four day 0 variants and the same number of day R variants.  
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2.  Monte Carlo uncertainty analysis 
a. Theory  
To accurately measure treatment success, estimates of the cure rate need to be 
adjusted for two types of misclassification: false positives (reinfections incorrectly being 
classified as recrudescent) and false negatives (true recrudescent infections misclassified 
as reinfections because a minority variant in the day 0 sample was not detected by 
nPCR).  To adjust for this misclassification, we developed an uncertainty analysis that 
requires two sources of external, or prior, information: the distributions of false positives 
and false negatives.  These distributions can be estimated using data from antimalarial 
efficacy studies.  
We developed a method for estimating the distribution of false positives that 
reflects our understanding of the factors that influence the probability of a chance match 
and exploits characteristics of the study data themselves, allowing the probability of a 
false positive to appropriately be tailored to the study setting.  False positive probabilities 
were calculated using the same simulation procedure described above, except that the 
number of allelic variants observed in each patient at day 0 and day R, and the 
population-wide distribution of allelic variants were set to match study data.  We used 
MATLAB R2008a (Natick, MA) to simulate the infection and reinfection of N patients, 
where N was the number of patients who participated in the study.  Each patient was 
assigned X day 0 variants and Y day R variants from the day 0 and day R distributions of 
allelic variants generated by genotyping parasites present in study samples (the X for 
each patient was randomly selected from the observed distribution of the number of day 0 
infections, the Y randomly selected from the distribution of the number of day R 
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infections) and tested for matches.  The false positive probability for this simulated study 
was then calculated as the number of chance matches divided by N.  We repeated this 
process 10,000 times (generating 10,000 false positive probabilities) to create the 
distribution of the proportion of recrudescent infections that were false positives. 
To estimate the distribution of false negatives, we made use of the observation 
that nPCR has limited sensitivity to variants comprising less than 20% of a patient’s 
parasite population.(30, 31)  Misclassification of a recrudescence as a reinfection, a false 
negative, requires that each day R variant be undetected in the day 0 variants, as a single 
shared variant will result in the classification of the recurrence as a recrudescence 
according to the MMV/WHO guidelines.(20)  To our knowledge, the only published 
information on the role of false negatives comes from Juliano et al. who used 
heteroduplex tracking assays (HTAs), a molecular method more sensitive to minority 
variants and genetic variation than nPCR, and found that five of six new infections (83%) 
identified by PCR-correction were truly recrudescent infections.(29)  However, their 
study population was at negligible risk of reinfection, likely making their results an 
overestimate in the context of an average antimalarial trial.  Therefore, to estimate the 
proportion of reinfections that were false negatives we used the median number of 
variants observed in the day R samples, assumed each variant carried with it a 20% 
chance of being missed in the day 0 sample, and calculated the probability that all were 
missed at day 0 resulting in a false negative using this formula: proportion of false 
negatives equals (0.2)v, where v is the median number of variants.  The 20% chance was 
based on existing literature and expert opinion.  We also conducted a sensitivity analysis 
varying the probability of a band being missed in the day 0 sample from 0 to 80%. 
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We conducted a Monte Carlo uncertainty analysis to adjust the observed number 
of recrudescent infections as determined by PCR-correction after genotyping msp2 by the 
estimated distributions of false positives and false negatives.  Using an approach similar 
to that described by Jurek et al.,(36) we calculate the adjusted cure rate using this 
formula: 
 
Adjusted cure rate = [Nt – (Nrecru – (Nrecru x FP) + (Nnew x FN))] / Nt (1) 
 
Where Nt is the total number of patients, Nrecru is the number of recrudescent infections 
identified by PCR-correction, FP is the proportion of recrudescent infections that were 
false positives, Nnew is the number of reinfections identified by PCR-correction, and FN 
is the proportion of reinfections that were false negatives.   
We used Oracle Crystal Ball, Fusion Edition (Redwood Shores, CA) software to 
run 100,000 trials in which the number of recrudescent infections as determined by PCR-
correction after genotyping msp2 in each study area was adjusted and the cure rate 
calculated using formula 1 (above).  As the last step in each trial, we included a bootstrap 
step to allow for sampling error by generating a random value from a binomial 
distribution in which the number of trials was equal to the number of patients in the study 
and the probability of success was the uncertainty-adjusted probability of treatment 
failure.  This approach is appropriate for estimating the sampling error of an estimated 
proportion.(74)  These random values were then used as the number of recrudescences to 
calculate the final cure rate, adjusted for both uncertainty and sampling error.  We also 
ran 100,000 trials without the bootstrap step to explore the effect of uncertainty in the 
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absence of sampling error, and finally, also calculated traditional 95% confidence 
intervals around the PCR-corrected cure rate with no adjustment for outcome 
misclassification to demonstrate the effect of sampling error in the absence of uncertainty 
about the outcome.  
b. Example data  
To provide an example of our proposed uncertainty analysis, we used genotyping 
data from two randomized antimalarial efficacy trials conducted in areas of differing 
transmission intensity.  The data from the high transmission area came from a study in 
Tororo, Uganda (N=401); the researchers were comparing the efficacy of an amodiaquine 
plus artesunate regimen compared to an atemether-lumefantrine regimen.(4)  The data 
from the low transmission area were generated by a study conducted in Bobo-Dioulasso, 
Burkina Faso (N=827); the researchers were comparing the efficacy of amodiaquine, 
sulfadoxine-pyrimethamine and amodiaquine plus sulfadoxine-pyrimethamine.(75)  In 
both studies, the different therapies did demonstrate different levels of efficacy(4, 75); 
however, because we are not interested in a particular treatment’s efficacy, and instead 
are simply providing an example of the uncertainty analysis, we did not stratify by 
treatment arm.  The data for each patient included the number and identity of allelic 
variants.  Greenhouse et al. used two sets of primers for amplification to capture two 
allelic families of msp2, IC3D7 and FC27.(5)  To prevent artificial chance-matches (a 
variant amplified with one set of primers that was 300bp is not the same as a variant of 
300bp amplified with the other set of primers), we added 1000bp to each variant 
identified by the FC27 primers to create a single distribution of msp2 variants that 
included both allelic families.   
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B.  The effect of HIV-1 protease inhibitors on incidence of malaria 
The AACTG conducted two phase III randomized clinical trials (ACTG5208) to 
measure HIV outcomes for HIV-infected women with and without previous NVP 
exposure when randomized to either LPV/r-based therapy or NNRTI-based therapy.  We 
conducted an ancillary study using the AACTG data to measure the association between 
LPV/r and clinical malaria in humans. 
 
1. ACTG5208 and selection of participants for ancillary study 
The AACTG screened and recruited HIV-infected, treatment-naïve women for 
participation in one of the two trials of which the parent-study was comprised.(40)  One 
trial enrolled women with no history of NVP exposure (N=502); the other trial enrolled 
women who had received single-dose NVP to prevent mother-to-child transmission of 
HIV(N=243).(40)  Once it was determined in which trial a participant was to be placed, 
she was randomly assigned (1:1) to a treatment arm.(40)   Participants were followed 
until 48 after weeks after the final participant was randomized.(40) 
In both trials, women were randomized to receive either LPV/r-based therapy or 
NNRTI-based therapy.  As a part of their therapy, all participants received two 
nucleoside reverse transcriptase inhibitors (NRTI) consistent with WHO treatment 
guidelines.(52)  The parent-study recommended emtricitabine and tenofovir; however 
clinicians at sites were encouraged to select the NRTIs used as he/she deemed most 
appropriate.(40)  
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   The AACTG enrolled women at least 13 years of age (or older as dictated by the 
study site IRB) with a CD4+ cell count < 200 cells/mm3 obtained within 90 days prior to 
study entry.  Additional biological parameters required for enrollment including: 
- Absolute neutrophil count ≥ 750/mm3 
- Hemoglobin ≥ 7.0 g/dL 
- Platelet count ≥ 50,000/mm3 
- Total bilirubin ≤ 2.5 x upper limits of normal   
 - Aspartate aminotransferase, Alanine aminotransferase, and  
   alkaline phosphatase ≤ 2.5 x upper limits of normal 
 - Negative pregnancy test within 45 days prior to study entry 
The study population was also subject to the following conditions: 
- All women who could potentially become pregnant must have agreed to use 
birth control for the duration of the study and for six weeks following the 
discontinuation of study medication. 
- All participants must have had a Karnofsky performance score ≥ 70 within 45 
days prior to study entry.  (A Karnofsky performance score characterizes 
functional impairment.)  
- Ability/willingness of participant (or legal guardian/representative) to give 
informed consent. 
- Intent to remain in current geographical area of residence and attend study visits 
as required. 
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 The study population did not include women confined in a correctional facility for 
legal reasons or in a medical facility for treatment of either a psychiatric or physical 
illness. 
 We used data from participants in both trials from all of the malaria-endemic 
study sites: Eldoret and Kericho, Kenya; Lilongwe, Malawi; Kampala, Uganda; Lusaka, 
Zambia; and Harare, Zimbabwe.   
 
2.  Study measures 
 a.  Main exposure 
 The main exposure was the therapeutic regimen to which the participant was 
randomized: LPV/r-based therapy or NNRTI-based therapy.  Participants receiving 
LPV/r were considered exposed; participants receiving an NNRTI were the referent 
group.  LPV/r is a co-formulation of two aspartic protease inhibitors used as part of 
antiretroviral regimens.  When used in combination, the RTV increases availability of 
LPV in the patient (the efficacy and tolerability of this combination of these drugs is 
reviewed in (76).  Aspartic protease inhibitors have exhibited antimalarial properties 
in multiple studies.(58, 59, 61-63, 71)  The NNRTI used in the study was NVP.  NVP 
is a widely used therapeutic agent, used in both NNRTI-based ART and as a single-
dose treatment to prevent mother-to-child transmission.  NVP has not demonstrated 
antimalarial action.(58, 62) 
 b.  Outcomes 
 We used two definitions of malaria: confirmed malaria and probable malaria 
(Table 2).  These definitions were developed by the trial staff.  Confirmed malaria 
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required both identification of Plasmodium sp. on a peripheral blood smear and 
“compatible clinical syndrome.” (ACTG materials)  Probable malaria required both a 
“compatible clinical syndrome” and antimalarial treatment employed or recommended. 
(ACTG material)  We also included patients who were prescribed antimalarials 
(amodiaquine, artemether/lumefantrine, artesunate, chloroquine phosphate, 
dihydroartemisinin/piperaquine, mefloquine HCl, pyrimethamine/sulfadoxine, quinine 
dihydrochloride, quinine sulfate or sulphalene/pyrimethamine) without a recorded 
diagnosis as probable cases.   
 Peripheral blood smears are used to identify parasites with microscopy and is 
considered the gold standard in malaria diagnosis.  Limitations to the approach 
include: low parasite densities may go undetected, variability in how samples are 
processed may lead to misdiagnosis and the microscopist must be highly trained.(77) 
An additional limitation in the context of this study was that the parent-study did not 
regularly collect blood smears as part of the protocol; instead they collected them 
when testing for malaria was appropriate based on the trial site’s standard of care 
guidelines.  Data describing the magnitude of participants’ parasitemia were 
unavailable.   
 c. Covariates:  The use of an intent-to-treat analysis simplifies our analysis as 
theoretically it controls for both measured and unmeasured confounders.  We 
stratified by trial and study site.   
 Use of concomitant medications with antimalarial activity, such as 
cotrimoxaole, could potentially modify the effect of the main exposure on the 
incidence of malaria.  Seasonal variation in malaria transmission intensity could also 
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modify that relationship.  We used product terms in the models to evaluate the impact 
of these two possible effect measure modifiers.  Using climate data from the National 
Oceanic and Atmospheric Administration and evidence from the literature(78-82), we 
created a dichotomous time-varying variable denoting rainy season (indicating a 
higher risk of malaria transmission).  We also created a time-varying dichotomous 
variable indicating current use of concomitant medications with antimalarial activity  
(azithromycin, clindamycin, diaminodiphenylsulfone, doxycycline hydrochloride, 
doxycycline monohydrate or trimethoprim/sulfamethoxazole). 
 
3.  Statistical analysis.   
 We conducted a discrete-time survival analyses (DTSA).  This required that 
the dataset be formatted so that each participant has multiple records, one for each 
period under observation until she either experienced the event (malaria) or 
completed follow-up (Appendix E).  We ran two final models: one in which both 
probable and confirmed cases were considered events and, as a sensitivity analysis, 
one in which only confirmed cases were considered events.  All analyses were intent-
to-treat.    
 a. Rationale and interpretation 
DTSA uses hazard functions to quantify the effect of predictors on event 
occurrence.  Hazard is the proportion of individuals at risk at the beginning of a time 
period experiencing the event (malaria), conditioned on having not experienced the event 
in an earlier time period.  DTSA affords several advantages.  By modeling not only event 
occurrence but also event timing, we were able to estimate the hazard of malaria across 
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different time periods, describing any patterns that exist and any difference in hazards 
between treatment arms over time.  Hazards may also be used to calculate survival 
probabilities, the proportion of the original study population that does not experience the 
event though successive time periods.  Survival analysis is a widely accepted approach 
with easily interpretable results.   
The parameters estimated by DTSA hazard models are simple to interpret (see 
Appendix F for the formula of the DTSA model); the alpha coefficients correspond to 
time period-specific baseline hazards (the hazards of the reference group), and the beta 
coefficients, when exponentiated, are the hazard ratio associated with a one unit change 
in the predictor in any time period.  (We used a pooled logistic regression model in which 
the exponentiated beta is a good estimate of the hazard ratio as long as the event 
proportion in all discrete time periods is less than 10%.)  In addition to presenting our 
estimated parameters and hazard ratios, we plotted logit hazards and survival 
probabilities to visualize the effect of therapeutic regiment on the hazard of malaria. 
 b. Assumptions  
Survival analyses include information from both censored and non-censored 
participants; this assumes that censoring is independent of event occurrence.  There are 
three key assumptions underlying the use of the discrete-time hazard model: 
1. Proportionality.  As in continuous-time survival analyses, the assumption of 
proportionality requires that the effect of a predictor does not vary across time; in the 
discrete-time survival analysis, this means that all of the logit-hazard profiles resulting 
from stratification by a predictor will have the same shape and be equidistant across all 
time periods.  It should be noted, however, that an interaction between time and another 
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predictor has been described as “the rule, rather than the exception.”(83)  Fortunately, a 
violation of this nature can be identified (and resolved) by including product terms 
(predictors*time) in the model and evaluating model fit.   
2. Linear additivity.  The discrete-time hazard model requires that one unit 
changes in the value of a predictor all have the same effect on the logit hazard.  One way 
this assumption can easily be tested is stratifying by predictor values, calculating the 
logit-hazard at each level of the predictor and plotting the values.  If single unit changes 
in the predictor generate equal displacements of the logit hazard, the assumption is met. 
Transformation or categorization of predictors that violate this assumption may achieve 
linearity.  On the logit scale, the combined effect of predictors is assumed to be additive 
(i.e. no statistical interaction).  This assumption will be explored by plotting stratified 
sample hazard functions and changes in model fit when interaction terms are included.    
3. No unmeasured heterogeneity.  “All variation in hazard profiles across 
individuals is hypothesized to depend solely on observed variation in the predictors.”(83)   
Unlike the other assumptions, violations of this assumption are not easily identified or 
rectified and the inclusion of an error term appears to be problematic.  However, because 
our data come from RCTs we do not anticipate that our models violated this assumption.   
            c. Model-building  
 The same model-building strategy was employed for both models (one in 
which either definition of malaria was considered an event, and when only confirmed 
cases were considered events).  The independent variable is the event indicator, a 
dichotomous variable that appears in each record of all participants.  We first created 
a model to assess the effect of time only.  We had weekly data with follow-up times 
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up to 144 weeks; creating indicator variables for each week, as is frequently done in 
DTSA, was inappropriate.  We explored multiple representations of time including: 
linear, quadratic, cubic, higher order polynomials, logarithmic transformations and 
restricted cubic splines using Harrell’s DASPLINE SAS macro.(84)  We used 
goodness of fit statistics to determine which representation of time improved model 
fit sufficiently to justify the reduction in parsimony.  Using product terms, we also 
explored whether the effect of therapy varied over time (if so, it would violate the 
proportionality assumption and the terms would be required in the model). 
Next we added our dichotomous exposure to the model (LPV/r-based therapy or 
NNRTI-based therapy).  We then added trial, study site, and other variables of interest 
into the model, one at a time.  Traditional model diagnostics such as deviance statistics 
and information criteria were employed to evaluate the benefit of adding these terms to 
the model.  We assessed effect measure modification through the inclusion of product 
terms and quantified their effect on the overall fit of the model using deviance statistics.   
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CHAPTER 3 
ADJUSTING FOR MISCLASSIFICATION IN ANTIMLALARIAL EFFICACY 
STUDIES 
 
A.  Summary 
Evaluation of antimalarial efficacy is difficult because recurrent parasitemia 
can be due to recrudescence (drug failure) or reinfection.  PCR is used to differentiate 
between recrudescences and reinfections by comparing parasite allelic variants before 
and after treatment.  However, PCR-corrected results are susceptible to 
misclassification:  false recrudescences, due to reinfection by the same variant present 
in the patient before treatment; and false reinfections, due to variants that are present 
but too infrequent to be detected in the pre-treatment PCR, but are then detectable 
post-treatment.  We explored factors affecting the probability of false recrudescences 
and proposed a Monte Carlo uncertainty analysis to adjust for both types of 
misclassification.  Higher levels of transmission intensity, increased multiplicity of 
infection, and limited allelic variation resulted in more false recrudescences.  The 
uncertainty analysis exploits characteristics of study data to minimize bias in the 
estimate of efficacy and can be applied to areas of different transmission intensity. 
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B.  Introduction 
The World Health Organization (WHO) recommends that first-line 
antimalarial treatment policies be changed when a drug’s cure rate falls below 90%, 
and that new treatments not be recommended unless they have a cure rate greater than 
95%.(14) However, defining the antimalarial cure rate is difficult in falciparum 
malaria clinical trials because recurrent parasitemias can result from either 
recrudescence (drug failure) or reinfection during follow-up.   
One tool used to distinguish between reinfection and recrudescence is PCR-
correction (or PCR-adjustment).  PCR-correction most often uses nested PCR (nPCR) 
to categorize recurrences by comparing size polymorphisms in genetic markers 
[merozoite surface proteins 1 and 2 (msp1, msp2) and glutamate rich protein (glurp)] 
before and after treatment.  PCR-correction of cure rates has been in use for more 
than 20 years and there is an extensive literature on the substantial impact it can have 
on estimates of treatment efficacy, as previously reviewed.(15, 17)  Variations in 
PCR-correction techniques exist, especially with regard to the interpretation of 
results.  In response to this variability, the Medicines for Malaria Venture (MMV) 
collaborated with the WHO to generate guidelines for PCR-correction including a 
definition of a recrudescent infection, namely a recurrence in which one or more 
allelic variants are shared in the pre-treatment (day 0) sample and the recurrent (day 
R) parasitemia.(20)  
PCR-correction is fallible.  Incorrect identification of a reinfection as a 
recrudescence occurs when the patient is infected with same variant before and after 
treatment; this is more likely to occur in an area with limited allelic diversity or high 
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transmission intensity.(5, 21) This type of misclassification results in underestimation 
of the cure rate.  Additionally, there are often multiple genetically distinct allelic 
variants present within a single host and nPCR is not capable of detecting minority 
variants representing <20% of the population.(85) Thus, PCR-correction could 
misclassify a recrudescence as a reinfection because an apparently “new” variant 
which appears in the day R sample was present, but not detected, in the day 0 
sample.(29)  This may be particularly important if drug resistant variants are at levels 
below detection initially but become more prevalent in the patient as other variants 
are cleared by the treatment.  This type of misclassification results in overestimation 
of the cure rate. 
This present work has two aims.  First, to demonstrate the effect of the 
distribution of allelic variants, transmission intensity and multiplicity of infection 
(MOI) on the probability of misclassification of recurrent infections.  Second, to 
develop a practical approach for adjusting PCR-corrected results for misclassification 
of both reinfections and recrudescences. A worked example using data from areas of 
both high and low transmission intensity is provided.   
 
C.  Methods 
1.  Characteristics affecting the probability of false positives 
We used simulations of the infection, cure, and re-infection process to 
demonstrate the effect of allelic diversity, transmission intensity and MOI on the 
probability of a false positive.  In this context, a false positive refers to a reinfection 
that is misclassified as a recrudescence because allelic variants in the day 0 and day R 
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samples match by chance.  We used MATLAB R2008a (Natick, MA) software to 
simulate infections (and re-infections) of individual patients after specifying the 
population-wide distribution of allelic variants.  For each of 100,000 simulated 
patients, we assigned a specified number of day 0 variants drawn randomly from the 
distribution.  We set treatment success at 100% and assigned a specified number of 
day R variants the same way.  We tested all patients for matching day 0 and day R 
variants, and calculated the probability of a false positive as the number of patients 
with a match divided by 100,000, the number of simulated patients.   
We first assessed the effect of allelic diversity in the parasite population on 
the probability of a false positive.  As in routine PCR-correction, allelic variants were 
distinguished by the number of base pairs (bp); due to the insensitivity of nPCR to 
small variations in the number of bp, variants that were different by no more than 
20bp were considered to be the same to replicate the degree of precision routinely 
allowed.  We used allelic distributions appearing in the literature to inform a plausible 
mean, 350bp, and a wide range of variances, from 1575 to 6475, to generate ten 
negative binomial distributions, shown in Figure 4.  The negative binomial 
distribution is believed to most accurately represent allelic distributions within 
parasite populations.(73)  For each distribution, we simulated the infection and 
reinfection of 100,000 patients by assigning each a single day 0 variant and a single 
day R variant drawn randomly from the distribution.   
 We assessed the effect of transmission intensity on the probability of a false 
positive by assigning each patient one day 0 variant and one, two, three or four day R 
variants, each reflecting an infectious bite (for simplicity, we assumed each infectious 
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bite transmitted a single variant).  We simulated the effect of MOI similarly, 
assigning each patient one through four day 0 variants and the same number of day R 
variants.  
 
2.  Monte Carlo uncertainty analysis 
To accurately measure treatment success, estimates of the cure rate need to be 
adjusted for two types of misclassification: false positives (reinfections incorrectly 
being classified as recrudescent) and false negatives (true recrudescent infections 
misclassified as reinfections because a minority variant in the day 0 sample was not 
detected by nPCR).  To adjust for this misclassification, we developed an uncertainty 
analysis that requires two sources of external, or prior, information: the distributions 
of false positives and false negatives.  These distributions can be estimated using data 
from antimalarial efficacy studies.  
We developed a method for estimating the distribution of false positives that 
reflects our understanding of the factors that influence the probability of a chance 
match and exploits characteristics of the study data themselves, allowing the 
probability of a false positive to appropriately be tailored to the study setting.  False 
positive probabilities were calculated using the same simulation procedure described 
above, except that the number of allelic variants observed in each patient at day 0 and 
day R, and the population-wide distribution of allelic variants were set to match study 
data.  We used MATLAB R2008a (Natick, MA) to simulate the infection and 
reinfection of N patients, where N was the number of patients who participated in the 
study.  Each patient was assigned X day 0 and Y day R infections from the observed 
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day 0 and day R distributions of allelic variants (the X for each patient was randomly 
selected from the observed distribution of the number of day 0 infections, the Y 
randomly selected from the distribution of the number of day R infections) and tested 
for matches.  The false positive probability for this simulated study was then 
calculated as the number of chance matches divided by N.  We repeated this process 
100,00 times (generating 10,000 false positive probabilities) to create the distribution 
of the proportion of recrudescent infections that were false positives. 
To estimate the distribution of false negatives, we made use of the observation 
that nPCR has limited sensitivity to variants comprising less than 20% of a patient’s 
parasite population.(30, 31)  Misclassification of a recrudescence as a reinfection, a 
false negative, requires that each day R variant be undetected in the day 0 variants, as 
a single shared variant will result in the classification of the recurrence as a 
recrudescence according to the MMV/WHO guidelines.(20) To our knowledge, the 
only published information on the role of false negatives comes from Juliano et al. 
who used heteroduplex tracking assays (HTAs), a molecular method more sensitive to 
minority variants and genetic variation than nPCR, and found that five of six new 
infections (83%) identified by PCR-correction were truly recrudescent infections.(29)  
However, their study population was at negligible risk of reinfection, likely making 
their results an overestimate in the context of an average antimalarial trial.  Therefore, 
to estimate the proportion of reinfections that were false negatives we used the 
median number of variants observed in the day R samples, assumed each variant 
carried with it a 20% chance of being missed in the day 0 sample, and calculated the 
probability that all were missed at day 0 resulting in a false negative using this 
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formula: proportion of false negatives equals (0.2)v, where v is the median number of 
variants.  The 20% chance was based on existing literature and expert opinion.  
Figure 5 shows our estimate of the effect of the number of variants in the day R 
sample on the probability that a recrudescence was misclassified as a reinfection (a 
false negative).  We also conducted a sensitivity analysis varying the probability of a 
band being missed in the day 0 sample from 0 to 80%. 
We conducted a Monte Carlo uncertainty analysis to adjust the observed 
number of recrudescent infections as determined by PCR-correction after genotyping 
msp2 by the estimated distributions of false positives and false negatives.  Using an 
approach similar to that described by Jurek et al.,(36) we calculate the adjusted cure 
rate using this formula: 
 
Adjusted cure rate = [Nt – (Nrecru – (Nrecru x FP) + (Nnew x FN))] / Nt (1) 
 
Where Nt is the total number of patients, Nrecru is the number of recrudescent 
infections identified by PCR-correction, FP is the proportion of recrudescent 
infections that were false positives, Nnew is the number of reinfections identified by 
PCR-correction, and FN is the proportion of reinfections that were false negatives.   
We used Oracle Crystal Ball, Fusion Edition (Redwood Shores, CA) software 
to run 100,000 trials in which the number of recrudescent infections as determined by 
PCR-correction after genotyping msp2 in each study area was adjusted and the cure 
rate calculated using formula 1 (above).  As the last step in each trial, we included a 
bootstrap step to allow for sampling error by generating a random value from a 
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binomial distribution in which the number of trials was equal to the number of 
patients in the study and the probability of success was the uncertainty-adjusted 
probability of treatment failure.  This approach is appropriate for estimating the 
sampling error of an estimated proportion.(74)  These random values were then used 
as the number of recrudescences to calculate the final cure rate, adjusted for both 
uncertainty and sampling error.  We also ran 100,000 trials without the bootstrap step 
to explore the effect of uncertainty in the absence of sampling error, and finally, also 
calculated traditional 95% confidence intervals around the PCR-corrected cure rate 
with no adjustment for outcome misclassification to demonstrate the effect of 
sampling error in the absence of uncertainty about the outcome.  
 
3.  Example data  
To provide an example of our proposed uncertainty analysis, we used 
genotyping data from two randomized antimalarial efficacy trials conducted in areas 
of differing transmission intensity.  The data from the high transmission area came 
from a study in Tororo, Uganda (N=401); the researchers were comparing the 
efficacy of an amodiaquine plus artesunate regimen compared to an atemether-
lumefantrine regimen.(4)  The data from the low transmission area were generated by 
a study conducted in Bobo-Dioulasso, Burkina Faso (N=827); the researchers were 
comparing the efficacy of amodiaquine, sulfadoxine-pyrimethamine and amodiaquine 
plus sulfadoxine-pyrimethamine.(75)  In both studies, the different therapies did 
demonstrate different levels of efficacy(4, 75); however, because we are not 
interested in a particular treatment’s efficacy, and instead are simply providing an 
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example of the uncertainty analysis, we did not stratify by treatment arm.  The data 
for each patient included the number and identity of allelic variants.  Greenhouse et 
al. used two sets of primers for amplification to capture two allelic families of msp2, 
IC3D7 and FC27.(5)  Alleles were considered different if they were from different 
allelic families or if they were not the same length.  
 
D.  Results 
1.  Characteristics affecting the probability of false positives 
The simulations compared the effect of transmission intensity and MOI on the 
probability of a false positive across ten negative binomial distributions comprising 
alleles with the same mean size (350bp) but different variances (Figure 4); increased 
variance signified higher levels of allelic (genetic) diversity in the population under 
study.  We drew 100,000 samples of allelic variants from each distribution, assumed 
100% treatment success, and drew a second variant to allow us to calculate the 
probability of a false positive.  We calculated these probabilities at different levels of 
transmission intensity and different MOI.    
At any level of allelic variance, the greater the number of post-treatment bites, 
or the more variants a patient had at day 0 and day R, the more likely a false positive.  
Conversely, higher levels of allelic diversity had lower probabilities of false positives 
regardless of transmission intensity or MOI (Figure 6). 
 
2.  Example of Monte Carlo uncertainty analysis 
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We used two data sets to provide examples of our Monte Carlo uncertainty 
analysis, which adjusted the number of recrudescent infections identified by PCR-
correction by false positives (the proportion of nPCR identified recrudescent 
infections misclassified due to a variant in the day 0 and day R sample matching by 
chance) and false negatives (the proportion of nPCR reinfections misclassified due to 
nPCR insensitivity).   
Patients from Tororo, the high transmission area, had one to eight day 0 
variants (median of four) and one to eight day R variants (median of three).  There 
were 40 variants in the day 0 sample when divided into 20 base pair bins with 
variants ranging in size from 181 to 1611bp (we had added 1000bp to variants 
amplified by primers specific to the FC27 allelic family to differentiate them from 
variants amplified by primers specific to the IC3D7 allelic family).  There were 38 
variants in the day R sample with sizes ranging from 212 to 1663bp. 
Patients from Bobo-Dioulasso, the low transmission area, had one to eight day 
0 variants (median of two) and one to six day R variants (median of two).  There were 
39 variants in the day 0 sample with sizes ranging from 195 to 1637bp.  There were 
25 variants in the day R sample with sizes ranging from 232 to 1565bp. 
a. False positives 
There was slightly less allelic diversity in Bobo-Dioulasso, however 
individuals with single pre-treatment and post-treatment variants had very similar 
probabilities of a false positive (in Tororo the probability was 0.050 vs. 0.045 in 
Bobo-Dioulasso).  In patients with the sites’ median numbers of pre-treatment and 
post-treatment variants (four and three respectively in Tororo; two and two in Bobo-
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Dioulasso), the probability of a false positive was considerably higher in Tororo 
(0.327) when compared to Bobo-Dioulasso (0.163). 
We used the probability of a day 0 and day R variant matching by chance to 
inform our distribution of false positives.  We did this by running 10,000 simulations, 
each with the number of participants in the study.  Each participant was assigned X 
day 0 and Y day R variants from the observed day 0 and day R distributions of allelic 
variants (the X for each patient was randomly selected from the observed distribution 
of the number of day 0 variants, the Y randomly selected from the distribution of the 
number of day R variants) and tested for matches.  We created a distribution of these 
10000 probabilities and determined its mean and standard error.  The mean 
proportion of recrudescent infections that were false positives was 0.423 in Tororo 
(standard error = 0.0007) and 0.193 in Bobo-Dioulasso (standard error = 0.0004). 
b. False negatives 
False negatives occur when a minority variant is undetected by the nPCR and 
results in misclassification of a recrudescent infection as a reinfection.  The 
proportion of variants likely to be false negatives was equal to (0.2)v, where 0.2 is the 
probability that a variant was missed in day 0 and v is the median number of variants 
in the site’s day R samples (Figure 5).  The proportion of reinfections that were false 
negatives was 0.008 in Tororo and 0.04 in Bobo-Dioulasso.   
c. Adjusted number of recrudescent infections 
There were 232 recurrent parasitemias among the 401 study participants from 
Tororo.  After genotyping msp2, 145 were classified as recrudescent and 87 as 
reinfection, corresponding to a cure rate of 63.8%.  After conducting our uncertainty 
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analysis, we determined that the 95% simulation interval of likely cure rates ranged 
from 74.6 to 83.3% (Table 1).   
Among the 827 study participants from Bobo-Dioulasso, there were 75 
recurrent parasitemias.  After genotyping msp2, 50 were classified as recrudescent 
and 25 as reinfection, corresponding to a cure rate of 94.0%.  After conducting our 
uncertainty analysis, we determined that the 95% simulation interval of likely cure 
rates ranged from 93.5 to 96.5% (Table 1).   
We evaluated the effect of uncertainty due to outcome misclassification and 
sampling error independently.  The adjustment for uncertainty regarding outcome 
misclassification was responsible for the upward shift of the cure rate (indicating 
greater efficacy) and sampling error increased the width of the simulation interval 
(Table 1).  
 
E.  Discussion 
Our simulations demonstrated the effect of allelic diversity, transmission 
intensity and MOI on the probability of a chance match between a day 0 and day R 
variant.  False positives were more common in areas with less diverse parasite 
populations and high transmission levels which would lead to underestimation of cure 
rates in those areas.  The most dramatic increase in the probability of a false positive 
was associated with increased MOI (Figure 6B).   
The results of the proposed uncertainty analysis indicated false positives 
(reinfections misclassified as recrudescences) were responsible for the majority of 
misclassification in both examples.  Selecting variants at random from the observed 
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distributions in Tororo resulted in false positives in more than one-third of the 
recrudescent infections, while in Bobo-Dioulasso the probability that a recrudescence 
was a false positive was less than 20%.  The discrepancy is primarily the result of the 
lower median day 0 and day R MOI in Bobo-Dioulasso, as both areas had similar 
levels of allelic diversity.  In Tororo, false positives resulted in an uncertainty interval 
of the cure rate that indicated greater efficacy than the original point estimate 
calculated after genotyping msp2.      
False negatives (recrudescences misclassified as reinfections) resulted in only 
a small amount of misclassification for two reasons.  First, multiple variants in the 
day R sample (observed in both study sites) decreased the probability of this type of 
misclassification exponentially (Figure 5).  Our sensitivity analysis indicated that 
even with a 30% chance that a day 0 variant was not detected, the impact of the 
observed number of variants in the day R samples resulted in a negligible effect of 
false negatives (data not shown). As the chance a day 0 variant was not detected 
increased past 40%, the impact began to increase more rapidly, however values 
greater or equal to 30% are highly unlikely.  Second, using PCR-correction there 
were very few recurrences identified as reinfections; regardless of the probability that 
a reinfection was truly a recrudescence, the contribution of this type of 
misclassification to overall uncertainty would be low. However, in areas of low 
transmission, such as Southeast Asia, where few variants are  
present a day 0, false negatives may be an important source of misclassification.(29)   
The uncertainty analysis was based on PCR-correction of a single marker.  
Though the use of multiple markers to perform PCR-correction (a common practice) 
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may reduce the probability of false positives, it increases the probability of false 
negatives because the MMV/WHO guidelines state that a single marker classified as a 
reinfection results in the recurrence being classified as such, regardless of the 
classification of other markers genotyped.  As additional information is generated 
regarding the probability of false negatives and how it changes with the use of 
multiple markers, it will be possible to refine this uncertainty analysis to 
accommodate multiple markers. 
The impact of misclassification with regard to WHO efficacy thresholds 
varied between the two sites.  Although ultimately the range of likely cure rates in 
Tororo did not cross a WHO cut-point, it did demonstrate that misclassification plays 
an important role.  In Bobo-Dioulasso, the area of low transmission, a WHO cut-point 
was included in the interval of likely cure rates (i.e. 93.5 to 96.5%).  The relatively 
few patients who had recurrent parasitemia in Bobo-Dioulasso resulted in a narrow 
interval of cure rates with values similar to the PCR-corrected point estimate, 
however a drug whose cure rate calculated the traditional way would have been just 
below the level of efficacy required for new drugs and may in turn have been 
rejected, when it should be eligible for consideration.  Misclassification should 
always be considered when policy decisions are made based on estimates of efficacy. 
Our approach to generating the distribution of false positives is probably not 
practical for use in all antimalarial efficacy studies.  However, we are optimistic that 
it is possible to generate three reasonable “stock” distributions of false positives, one 
for high, medium, and low transmission areas.  The uncertainty analysis itself is quite 
straightforward and can easily be carried out in Crystal Ball, a relatively inexpensive 
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addition to Microsoft Excel, and perhaps eventually in a free web-based tool.  It is our 
hope that future molecular research will allow us to provide researchers with 
distributions of false positives and false negatives, making this uncertainty analysis 
available for wide use. 
Misclassification of recurrent parasitemias resulting from PCR-correction has 
been previously described.  Adjustments of PCR-corrected trial results have been 
made using the distribution of allelic variants to calculate the probability of false 
positives leading to incorrect classification of the recurrence as a recrudescence when 
it is a reinfection.(5, 21, 28, 33) HTAs, which use radiolabeled probes to bind to host 
amplicons, are more sensitive to minority variants and genetic variation than 
nPCR(21, 30, 86, 87) and have been used to demonstrate that nPCR insensitivity can 
result in recrudescent infections being misclassified as reinfections.(29)  To our 
knowledge, simultaneous adjustment for both types of misclassification has not been 
undertaken previously. 
Traditional confidence intervals summarize only the effect of random error 
and do not capture or reveal any uncertainty resulting from bias, including 
misclassification or measurement error, in the study.  Adjusting results for 
misclassification was illustrated in previous work(36) and is grounded in methods 
proposed to estimate intervals that are an extension of traditional confidence intervals 
through use of simulations.(34)  Some researchers are uncomfortable with the explicit 
assumptions about misclassification that are required for uncertainty analyses.  
However, this approach is far preferable to assuming misclassification is entirely 
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absent, an implicit assumption in the traditional estimation of a PCR-corrected cure 
rate. 
A point estimate of the cure rate, the traditional outcome measure in 
antimalarial efficacy studies, is insufficient given the limitations of PCR-correction.  
This insufficiency is even more important given the policy implications of efficacy 
estimates.  A 95% simulation interval for the cure rate, instead of an estimate likely to 
be biased by outcome misclassification, may encourage more careful assessment of a 
treatment’s utility before policy decisions are made.  This work provides a template 
for adjusting for outcome misclassification in antimalarial efficacy studies that 
addresses both types of misclassification and can be applied to any study data that 
include information on the variants present in the patient population. 
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Figure 4. The ten negative binomial distributions of base pairs used for 
simulations.  These distributions all have the same mean (350 bp); the variance 
increases from top to bottom.  Each plot represents 100000 randomly assigned 
number of base pairs selected from the distribution.  x-axis: number of base pairs; y-
axis: frequency 
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Figure 5.  Multiplicity of infection and its effect on the probability of a false 
negative.  A false negative, or a recrudescent infection misclassified as a reinfection, 
occurs as a result of nPCR insensitivity to minority variants (those comprising less 
than 20% of a patient’s infection). 
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Figure 6. A) The effect of transmission intensity on the probability of a false 
positive, B) The effect of multiplicity of infection on the probability of a false 
positive.  x-axis: measure of allelic variation in parasite population (1 = least 
variance); y-axis: probability of a false positive (a false positive occurs when a day 0 
and day R variant match by chance); var = variant 
 
 
 
 
 
 
 
 
 
B) A) 
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Table 2. Results from the uncertainty analysis: estimates of cure rates from 
studies in Bobo-Dioulasso, Burkina Faso, and Tororo, Uganda.   
 Tororo 
N = 401 
Bobo-
Dioulasso 
N = 827 
Number of recurrent infections 232 75 
Number of recrudescent infections identified by 
PCR-correction based on genotyping of msp2 
145 50 
Cure rate (95% CIa) calculated by PCR-correction 
based on genotyping of msp2 (%) 
63.8 
(59.0 – 68.4) 
94.0   
(92.1 – 95.4) 
95% SIb of likely cure rates adjusted for only for 
uncertainty (%)c 
77.4 – 80.5  94.9 – 95.1 
95% SI of likely cure rates generated by Monte 
Carlo uncertainty analysis (%) 
74.6 – 83.3 93.5 – 96.5 
a. CI = confidence interval; b. SI = simulation interval; c. This interval does not take sampling error 
into account. 
  
 
 
CHAPTER 4 
HIV-1 PROTEASE INHIBITORS AND INCIDENT MALARIA: AN ANCILLARY 
STUDY TO ACTG5208 
 
A.  Summary 
HIV-1 protease inhibitors (HIV PIs) have antimalarial action in vitro and in 
murine models.  The effect of HIV PIs on malaria has never been studied in humans. 
We used data from ACTG5208 to compare incidence of clinical malaria in 
HIV-infected adult women randomized to PI-based antiretroviral therapy (ART) to 
women randomized to non-nucleoside reverse transcriptase inhibitor (NNRTI)-based 
ART.  We used pooled logistic regression to calculate hazard ratios and 95% 
confidence intervals.  We conducted a stratified analysis and explored effect measure 
modification by seasonality and concomitant medication use.   
 ART assignment was not associated with the hazard of malaria (HR = 
1.03; 95% CI: 0.73 - 1.44).  This finding was similar in analyses stratified by trial 
[Trial 1, HR = 1.37 (95% CI = 0.76 - 2.44); Trial 2, HR = 0.94 (95% CI = 0.62-
1.43)].  There was no modification of the HR by seasonality or use of concomitant 
medications.  
Clinical malaria among HIV-infected individuals was not reduced by PI-based 
ART.  This study is the first step in understanding whether HIV PIs will reduce 
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malaria and additional work focused on incidence of sub-clinical malaria and malaria 
in children may be warranted. 
 
B.  Introduction  
HIV and malaria are highly co-prevalent in some regions of the world, 
including Sub-Saharan Africa.  These infectious agents interact biologically such that 
each may increase incidence of the other.(42)  A treatment efficacious against both 
diseases or an antiretroviral that provided prophylaxis for malaria would offer a 
tremendous advantage to the millions of HIV-infected people in areas where co-
infection is common.   
The biological interaction between the two diseases is well documented 
though incompletely understood.  HIV infection increases incidence and worsens 
clinical manifestations of malaria(43-45); malaria elevates HIV viral load(47, 48) and 
decreases CD4 counts.(51)  The data on drug interactions between antiretroviral 
therapies (ART) and antimalarials are incomplete.  However, there are examples of 
harmful effects for the patient and alterations in the pharmacokinetics of the 
treatments, reviewed in (54)  The biological and pharmacological interactions make a 
treatment effective against both diseases highly desirable.  There is evidence that HIV 
protease inhibitors (PIs) may fill that role.(58, 59, 61-63, 71)   
Evidence that aspartic PIs (the group of PIs used in HIV ART) have 
antimalarial effects on Plasmodium falciparum, the most virulent of the human 
malaria-causing parasites, was first generated more than two decades ago.(88)  More 
recent in vitro studies have demonstrated that HIV PIs inhibit the growth of P.  
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falciparum, regardless of the parasites’ sensitivity to antimalarials(58, 59), and 
parasites exposed to sera taken from HIV-infected patients being treated with LPV/r 
had a 50 to 95% reduction in growth.(62) In vivo evidence from murine models also 
supports the antimalarial effect of HIV PIs.(61, 63)  Nathoo et al. proposed that HIV 
PIs may have an impact on patients with malaria independent of antiparasitic effects 
after observing in vitro that treating cells with HIV PIs resulted in a marked reduction 
in the expression of CD36, a human cell receptor associated with the binding of 
malaria parasites.(72)  
 Protease inhibitors are not currently recommended for first-line ART use in 
resource limited settings.(38)  However the recent advent of heat stable LPV/r, 
coupled with observed resistance to first-line non-nucleoside reverse transcriptase 
inhibitor (NNRTI)-based ART (39) and resistance to nevirapine (NVP) associated 
with use of single dose NVP for prevention of mother-to-child transmission of 
HIV(89), makes it likely the use of PIs in the developing world will increase.  If the 
antimalarial effect of HIV PIs is also found to be present in humans, their use in 
regions with endemic malaria would be even more valuable.  
The Adult AIDS Clinical Trials Group (AACTG) recently completed two 
phase III randomized clinical trials (ACTG5208) to compare the antiretroviral activity 
of LPV/r-based ART to NNRTI-based ART in HIV-infected women who either had 
been exposed to single dose NVP (Trial 1) or were treatment-naïve (Trial 2).  We 
conducted an ancillary study using the AACTG data to measure the association 
between LPV/r and clinical malaria in humans  
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C.  Methods  
1.  ACTG5208.   
The study consisted of two trials that followed participants for 48 weeks after 
the final participant was randomized.(40)  Trial 1 enrolled women who had received 
single-dose NVP to prevent mother-to-child transmission of HIV (N=243); Trial 2 
enrolled women with no history of NVP exposure (N=500).(40)  In both trials, 
women were randomized 1:1 to receive either LPV/r-based ART or NNRTI-based 
ART.  All participants received tenofovir DF and emtricitabine consistent with World 
Health Organization (WHO) guidelines.(52)  Participants had regularly scheduled 
study visits (at weeks 2, 4, 8, 12, 16, 24 and then every 12 weeks) and could also 
report to the study site for medical care as needed. 
 
2.  Study population.  
 ACTG5208 enrolled women greater than 13 years of age (or older as dictated 
by the study site IRB) with a CD4+ cell count < 200 cells/mm3 obtained within 90 
days prior to study entry.  Enrollment criteria are described in detail elsewhere.(40)  
We used data from participants in both trials from all of the study sites where malaria 
is endemic: Eldoret and Kericho, Kenya; Lilongwe, Malawi; Kampala, Uganda; 
Lusaka, Zambia; and Harare, Zimbabwe.   
 
3.  Exposure and outcome.   
 The main exposure was the therapeutic regimen to which the participant was 
randomized (i.e., LPV/r-based ART or NNRTI-based ART).  The primary outcome 
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was clinical malaria.  The trial staff classified this diagnosis as probable or confirmed.  
Probable malaria required both a “compatible clinical syndrome” and use or 
recommendation of antimalarial treatment.(40)  Confirmed malaria required both 
“compatible clinical syndrome” and identification of Plasmodium sp. on a peripheral 
blood smear.(40)  We also included patients who were prescribed antimalarials 
(amodiaquine, artemether/lumefantrine, artesunate, chloroquine phosphate, 
dihydroartemisinin/piperaquine, mefloquine HCl, pyrimethamine/sulfadoxine, 
quinine dihydrochloride, quinine sulfate or sulphalene/pyrimethamine) without a 
recorded diagnosis of malaria as probable cases.   
 
4.  Statistical analysis.   
 We counted person-time at risk from treatment initiation until the date of 
malaria, death, drop-out, or study completion. We used the hazard ratio (HR) as a 
measure of association and the 95% confidence interval (CI) as a measure of 
precision. To obtain the hazard ratio we fit pooled logistic regression models, 
which approximate Cox proportional hazards models(90) as long as the event 
proportion in all discrete time periods is less than 10%.; in our study the largest 
event proportion was 5.6%. Time-on-treatment was modeled using a 5-knot 
restricted cubic spline (Harrel’s DASPLINE(84)) to allow a flexible nonlinear 
association between time and malaria and all models included trial and study site.  
Because few patients had greater than 165 weeks of follow-up and there were no 
incidences of malaria after that time, we administratively censored all participants 
still at risk at 165 weeks.  
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 We examined seasonality and concomitant medication use as possible 
effect measure modifiers by the addition of product terms with exposure. Using 
climate data from the National Oceanic and Atmospheric Administration and 
evidence from the literature(78-82), we created a time-varying dichotomous 
variable denoting rainy season (indicating a higher risk of malaria transmission). 
We also created a time-varying dichotomous variable indicating current use of 
concomitant medications with antimalarial activity (azithromycin, clindamycin, 
diaminodiphenylsulfone, doxycycline hydrochloride, doxycycline monohydrate or 
trimethoprim/sulfamethoxazole). We examined the proportional hazards 
assumption by a plot of the log cumulative hazard by time as well as the addition 
of terms for the products of exposure and time (including spline coefficients). We 
conducted a stratified analysis in which we explored the effect of LPV/r in Trial 1 
and Trial 2 separately.  As a sensitivity analysis, we fit a model in which only 
confirmed malaria cases were considered to have experienced a malaria episode.  
Finally, we generated plots of survival by time for each exposure group.  All 
analyses were conducted using SAS statistical software (version 9.2; SAS 
Institute, Cary, NC).  
 
D.  Results  
 There were 145 women enrolled in Trial 1 from the relevant sites.  They  
were split almost evenly between treatment arms, were similarly aged, and had 
comparable baseline CD4 counts and HIV viral loads (Table 3).  Participants in 
Trial 1 were followed for up to 144 weeks; the average duration of follow-up was 
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63 weeks.  In Trial 1, 48 participants (33%) were identified as having probable or 
confirmed malaria at least once during follow-up (Table 4).  Of those, 20 (42%) 
participants had more than one episode of malaria. 
 There were 301 women enrolled in Trial 2 from the relevant sites (Table 
3).  There were seven more women randomized into the LPV/r-based ART arm 
compared to the NNRTI-based ART arm.  The average age in Trial 2 was slightly 
higher than in Trial 1 but similar across treatment arms within Trial 2.  Baseline 
CD4 counts and viral loads were similar although there was a slightly higher 
proportion of patients with a baseline CD4 count < 50 cell/mm3 in the LPV/r arm 
(Table 1).  Participants in Trial 2 were followed for up to 185 weeks; 23 were 
administratively censored at 165 weeks.  The average duration of follow-up was 
88 weeks.  In Trial 2, 89 participants (30%) were identified as having probable or 
confirmed malaria at least once during follow-up (Table 4).  Of those, 41 (46%) 
participants had more than one episode of malaria. 
 The proportional hazards assumption was met.  Neither seasonality nor 
concomitant use of medications with antimalarial effect modified the effect of 
treatment assignment on the hazard of malaria (results not shown).  When we 
adjusted for trial and site, treatment assignment was not associated with the 
hazard of malaria (HR = 1.03; 95% CI: 0.73 - 1.44).  A survival curve in which 
trial and site are collapsed is presented in Figure 7.  Trial and site-specific curves 
are available in Appendix H.     
 When we considered only laboratory confirmed cases of malaria, the 
results were very similar; there was no effect of treatment assignment on the 
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hazard of malaria (HR = 1.28; 95% CI: 0.58 - 2.82).  This finding was similar in 
analyses stratified by trial [Trial 1, HR = 1.37 (95% CI = 0.76 - 2.44); Trial 2, HR 
= 0.94 (95% CI = 0.62-1.43)].  Trial-specific curves are presented in Figure 8. 
 
E.  Discussion 
Laboratory evidence supports the antimalarial effect of HIV PIs. The effect 
has been shown in cultured parasites, both drug sensitive and drug resistant, and in 
mice using two murine species of Plasmodium.  Skinner-Adams et al. reported that 
ritonavir (RTV), one of the PIs used in ACTG5208, and another HIV PI inhibited 
growth in parasites in vitro whereas the antiretroviral NVP had no effect.(58)  These 
findings have been replicated and additional HIV PIs have demonstrated antimalarial 
effects at clinically relevant concentrations.(59, 62) 
Studies of murine models of malaria also have demonstrated the antimalarial 
effect of HIV PIs.  After infection with P. chabaudi, mice exposed to LPV/r had 
delayed onset of parasitemia by two days and a decrease in median parasitemia from 
20% to 4%.(61)  Evidence from a different murine model, P. yoelii, suggested that 
HIV PIs, including LVP, the other ACTG5208 PI, inhibit growth of preerythrocytic-
stage parasites.(63)  
Unlike these laboratory studies, we saw no evidence of an antimalarial effect.  
Patients randomized to LPV/r-based ART were as likely to develop malaria as those 
randomized to receive NNRTI-based ART. 
We propose two potential reasons that may help to explain why no effect was 
observed.  One possibility is that any antiparasitic action of the LPV/r occurs 
simultaneously with a reduction in the innate immune response to malaria resulting 
 74 
 
 
from exposure to LPV/r, resulting in a null net benefit.  Nathoo et al. proposed that 
although the decrease in CD36 expression may be beneficial to the patient because of 
decreased cytoadherence of parasitized erythrocytes, it could also make it more 
difficult for a patient’s innate immune system to fight P. falciparum infections 
because of reduced phagocytosis which also resulted from the diminished expression 
of CD36.(72)   
Another possibility is that the antimalarial effects of PIs are highly 
concentration-dependent.  The in vitro studies of HIV PIs on malaria parasites strove 
to explore the effect using clinically relevant concentrations, including trough 
concentrations.(58, 59, 61, 62) However it is unknown if the parasites’ exposures to 
drugs in the laboratory studies are truly equivalent to the fluctuating serum drug 
concentrations one would anticipate in a patient on ART.  Carefully controlled 
laboratory experiments, isolated from the complex biological interactions among 
drugs, host acquired and innate immunity, and in vivo parasite growth dynamics, may 
simply not approximate the experience of HIV-infected patients on PI-based ART. 
Women assigned to NNRTI-based ART in Trial 1 were more likely to 
experience virologic failure when compared to the women randomized to LPV/r-
based ART.(CROI 2009 abstract)  This reduced control of HIV disease could have an 
impact on our findings as increased incidence of clinical malaria has been associated 
with low CD4 counts in HIV-infected individuals.(43, 45)  Had we observed a 
protective effect of LPV/r, it would have been important to consider that it may 
simply have resulted from the superior virologic response to that therapy.  It is of note 
that in Trial 2, LPV/r-based ART and NNRTI-based ART had comparable virologic 
 75 
 
 
efficacy (CROI 2010 abstract) and in our stratified analyses there was no effect of 
LPV/r on incidence of malaria in either trial. 
Women who experienced virologic failure, as well as those with adverse 
reactions to their assigned medications, were eligible to switch antiretroviral therapies 
and receive the treatment available in the other study arm.  Among the 346 women 
included in this ancillary analysis, 50 (14%) did so; almost all moved from NNRTI-
based ART to LPV/r-based ART.  Because it is a relatively small percentage of 
patients who switched treatments and because fewer than 10% of the malaria episodes 
occurred after the participant had switched, we do not anticipate that this had a 
considerable effect on our findings.   
This work has several limitations primarily related to the outcome.  The 
sensitivity and specificity of clinical syndrome when used to diagnose malaria are 
notoriously limited (Steve Taylor, personal communication, (91)).  When an exposure 
is dichotomous, nondifferential misclassification (we do not anticipate the sensitivity 
and specificity would vary across treatment arm) usually drives effect estimates 
towards the null.  It is possible that this partially explains our null results.  
Additionally, the ACTG5208 study staff did not regularly collect blood smears as part 
of the protocol; instead they collected them when testing for malaria was appropriate 
based on the site’s standard of care guidelines.  The lack of systematically collected 
blood smears and the absence of information with regard to blood smears that were 
negative, made slide-positivity an unacceptable primary outcome.   
This work is only the first step in understanding the antimalarial effects of 
HIV PIs in humans.  “Probable” malaria without laboratory confirmation is an 
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imperfect outcome.  However, the comparable effect estimates generated by models 
that included both probable and confirmed cases, and the sensitivity analysis in which 
only confirmed cases were considered to have malaria strengthen our findings.   
The use of biological markers will allow future investigations into the impact 
of HIV PIs on sub-clinical malaria.  Further research is also warranted on the effects 
of these drugs in children, who are at greater risk of clinical malaria.  Additionally, 
laboratory evidence suggests that co-administering HIV PIs with chloroquine or 
mefloquine may enhance the antimalarial activity of the drugs even in resistant 
parasites; perhaps the utility of HIV PIs as antimalarials will result from co-
administration with existing therapeutics.  The optimism about HIV PIs having an 
antimalarial effect in HIV-infected individuals may need to be tempered, but there is 
still much to be learned. 
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Figure 7.  Survival curves by treatment assignment for participants in 
ACTG5208.   
 
 
Figure 8.  Trial-specific survival curves for participants in ACTG5208.  (A) 
Trial 1.  (B) Trial 2.   
 
 
A B 
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Table 3.  Participants in ACTG5208 by trial and treatment group from sites 
with endemic malaria. 
 Trial 1  
(n = 145) 
Trial 2 
(n = 301) 
 LPV/ra 
(n = 72) 
NPVb 
(n = 73) 
LPV/ra 
(n = 154) 
NPVb 
(n = 147) 
Age, years 30.5 30.7 35.8 34.8 
Site, n     
     Eldoret, Kenya 9 8 25 22 
     Kericho, Kenya 14 13 23 23 
     Lilongwe, Malawi 10 14 22 22 
     Kampala, Uganda 9 8 21 22 
     Lusaka, Zambia 12 12 21 19 
     Harare, Zimbabwe 18 18 42 39 
Baseline CD4,   
  mean cells/mm3 ± SDc 
126 ± 57 134 ± 62 123 ± 78 127 ± 81 
Baseline CD4 <50, n(%) 7 (9.7) 10 (13.7) 27 (17.5) 20 (13.6) 
Baseline HIV-1 RNA,       
  median copies/mLd 
157,453 161,630 131,175 112,401 
aLopinavir boosted with ritonavir–based antiretroviral therapy.  
 
bNevirapine–based antiretroviral therapy.  
 
cCD4-positive cells per mm3.  dLog HIV-1 viral load. 
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Table 4. Clinical malaria among participants of ACTG5208.    
 Trial 1 
n = 145 
Trial 2 
n = 301 
 LPV/r (n) NVP (n) LPV/r (n) NVP (n) 
All malaria, n     
     Eldoret, Kenya 5 5 5 8 
     Kericho, Kenya 8 6 12 10 
     Lilongwe, Malawi 7 5 7 8 
     Kampala, Uganda 3 0 6 9 
     Lusaka, Zambia 3 6 12 8 
     Harare, Zimbabwe 0 0 2 2 
Total  26 22 44 45 
     
Confirmed malaria, n 4 3 10 8 
 
 
 
 
 
  
 
CHAPTER 5 
DISCUSSION 
A.  Factors influencing PCR-corrected cure rates in antimalarial efficacy trials 
1.  Summary of findings 
  We identified factors that influence outcome misclassification and used them 
to develop a Monte Carlo uncertainty analysis; our findings suggested that false 
positives (incorrectly identified treatment failures) are common in antimalarial 
efficacy studies and result in underestimates of treatment efficacy.  We conducted an 
intuition-building exercise which relied exclusively on simulated data.  As 
anticipated, holding transmission intensity and multiplicity of infection constant, 
increased allelic diversity reduced the probability of the same variants being observed 
before and after treatment by chance (a false positive).  Conversely, holding allelic 
diversity constant, increased transmission intensity and multiplicity of infection 
increased that probability.  From our simulations, it was clear that we would need to 
consider these factors in the development of our Monte Carlo uncertainty analysis. 
 During the development of the Monte Carlo uncertainty analysis, we relied 
heavily on statistical methods employed by Jurek et al.(36) and probability-based 
corrections of molecular data used by malariologists(5, 21, 28, 33).  Having identified 
important factors associated with outcome misclassification in our simulation 
exercises and used the literature to estimate the likely role of PCR-insensitivity to 
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minority variants, we worked to design a practical approach that could be useful to 
clinicians and others associated with antimalarial treatment trials.   
 The model we created used a straight-forward approach, with some technical 
details:  (1) remove the proportion of infections believed to be false positives from the 
pool of study participants classified as treatment failures by PCR (this requires a 
distribution of the probability of false positives); (2) move the proportion of 
infections believed to be false negatives from the pool of patients classified as 
reinfections into the pool of treatment failures (this requires an estimate of the 
probability of false negatives); (3) use the adjusted pool of treatment failures to 
calculate a new cure rate; (4) use a nonparametric bootstrap step to generate random 
error around the cure rate; (5) repeat this process 100,000 times and generate a 95% 
simulation interval of likely cure rates.   
When we conducted the uncertainty analysis using data from two separate 
trials conducted in low and high transmission areas, we discovered that the 
probability of false positives was quite high in the high transmission site (33%) and 
lower but still unexpectedly high in the low transmission site (16%).  In both sites, the 
likely impact of false negatives appeared negligible.  The initial estimate of the cure 
rate in the high transmission area was 63.8%; after we used our uncertainty analysis 
to adjust the estimate for outcome misclassification, the 95% simulation interval of 
the cure rate was 74.6 to 83.3%.  The initial estimate of the cure rate in the low 
transmission area was 94.0%; after the uncertainty adjustment the 95% simulation 
interval of the cure rate was 93.5 to 96.5%. 
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2.  Findings in the context of current literature 
It is not uncommon in the literature to find mention of the possibility of 
outcome misclassification, especially the erroneous classification of new infections as 
treatment failures, but it is almost always dismissed as unimportant.  Publications that 
used data on the distribution of allelic variants in the parasite population to adjust 
estimates of treatment efficacy beyond those generated by PCR-correction have 
shown that using this additional source of information to assess the probability of 
false positives likely improves estimates of the cure rate.(5, 21, 28, 33)  
This project builds on those studies by incorporating not only information 
related to the probability of false positives but also uses data on PCR-insensitivity(30, 
31) to estimate the impact of false negatives.  To our knowledge, there is only one 
paper that has addressed the impact of false negatives and they estimated that a 
majority of “reinfections” were truly treatment failures.(29)  This is quite different 
then our findings, in which only a small percentage (1 to 4%) of patients were likely 
misclassified in that way.  However, their study population was not at risk for 
reinfection due to hospitalization throughout follow-up or very low local transmission 
intensity; this makes their results not generalizable to the majority of treatment trials.  
 
3.  Strengths and limitations  
a.  Strengths 
The uncertainty analysis we developed is straight-forward and, if study site-
appropriate distributions of false positives and negatives are provided, can be 
executed with little statistical expertise or knowledege of statistical software.   
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The ability to exploit characteristics of the study data themselves also makes 
this analysis a desirable option.  This allows for the inclusion of information we know 
to be important to misclassification, namely the distribution of genetic variants and 
the MOI.  Additionally, explicit assumptions regarding the degree of misclassification 
is unappealing to some researchers.  By tailoring these assumptions to the study site, 
and incorporating data that have been shown to be relevant to outcome 
misclassification, we demonstrate that these estimates of misclassification are not 
solely the results of “stastistical hand-waving.” 
b.  Limitations 
Malaria biology is complex.  Human host immunity, genetic diversity of 
parasites within a single infectious bite, and sequestration and synchronicity of 
parasites, are only a few of the factors at work in the complicated dynanmics of 
malaria infection.  Our analysis cannot address many of those factors and requires a 
number of assumptions. 
One particular component of the analysis which we believe could be improved 
upon as additional data are generated is the role of false negatives.  There is no 
relevant evidence to demonstrate their impact on study populations at risk for 
reinfection.  Using information on the insensitivity of nPCR to minority variants and 
relying on the WHO/MMV guidelines on classifying a recurrent infection as new, we 
were able to estimate what we hope is a reasonable approximation, but as additional 
molecular data become available that are generated using very sensitive and precise 
techniques to identify all variants present in a host it is likely an updated 
approximation would be closer to the truth.  
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 Our objective was to develop a tool that would be useful for clinicians and 
clinical trial specialists and would not require a great deal of statistical sophistication.  
Once the distributions of false positives and negatives have been developed, the 
actual adjustments we made are uncomplicated.  However, the generation of the 
distributions of false positives required a significant amount of programming in 
MATLAB R2008a (Natick, MA).  The programming would not be difficult to anyone 
accustomed to statistical software but it may be a disincentive to those without the 
inclination.  
 
4.  Implications 
 This project demonstrated that false positives may indeed have a large effect 
on estimates of the cure rate and that as currently calculated, PCR-corrected cure rates 
may underestimate drug efficacy. 
If reliable estimates of the distributions of false positives and negatives can be 
generated for a range of transmission areas, this project lays the groundwork for the 
development of a web-based tool to be used by antimalarial efficacy researchers.  
Members of our laboratory are in the process of developing highly sensitive 
molecular techniques to determine which variants are in a patient’s sample and they 
can then compare those findings with the variants identified by PCR.  These data will 
allow us to generate transmission intensity-specific probabilities of false negatives 
and we are also considering developing additional transmission intensity-specific 
distributions of  false positives.  We would then collaborate with programmers to 
generate a web-based tool that would allow researchers to enter their study results 
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based on PCR-correction and estimates of transmission intensity for their study site 
and have the uncertainty analysis run for them. 
Whether use of this analysis is adopted will rely on whether trialists and other 
researchers believe that it makes sense to incorporate this type of correction for 
outcome misclassification. 
If nothing else, this work demonstrates that ignoring outcome 
misclassification, as is so commonly done in this area of study, results in erroneous 
findings.  This makes the approach of using stringent cutpoints based on PCR-
corrected cure rates to determine what is a suitable antimalarial treatment policy 
undesirable. 
 
B.  The effect of HIV-1 protease inhibitors on incidence of malaria 
1.  Summary of findings. 
 There was no association between receipt of PI-based ART and incidence of 
malaria in this study.  We used pooled logitic regression to conduct a survival 
analysis comparing the incidence of clinical malaria between HIV-infected women 
assigned to LPV/r-based ART and women assigned to NNRTI-based ART.  We saw 
no evidence of an effect when we considered both confirmed and probable cases (HR 
= 1.03; 95% CI: 0.73 - 1.44), nor in our sensitivity analysis in which only confirmed 
cases were considered to have malaria (HR = 1.28; 95% CI: 0.58 - 2.82).  In analyses 
stratified by trial, we also saw no effect [Trial 1, HR = 1.37 (95% CI = 0.76 - 2.44); 
Trial 2, HR = 0.94 (95% CI = 0.62-1.43)]. 
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We assessed possible modification of the hazard ratio by seasonality and use 
of concomitant medications but did not observe such modification.   
 
2.  Findings in the context of current literature 
 This is the first time the effect of HIV PIs on incidence of malaria in humans 
has been studied.  Our finding of no effect is inconsistent with laboratory results.  In 
cultured parasites, both drug sensitive and drug resistant, and in mice using two 
murine species of Plasmodium, HIV PIs inhibit parasite growth.(58, 59, 61-63)  
Skinner-Adams et al. first reported that RTV, one of the PIs used in ACTG5208, as 
well as another HIV PI inhibited growth in parasites(58); these findings have been 
replicated and additional HIV PIs have demonstrated antimalarial effects at clinically 
relevant concentrations.(59, 62) 
Animal studies have also demonstrated the antimalarial effect of HIV PIs.  
After infection with P. chabaudi, mice exposed to LPV/r had delayed onset of 
parasitemia by two days and a decrease in median parasitemia from 20% to 4%.(61)  
Evidence from a different murine model, P. yoelii, suggested that HIV PIs, including 
LPV, the other ACTG5208 PI, inhibit growth of preerythrocytic-stage parasites.(63)  
There is, however, one article to our knowledge that may be consistent with 
our findings.  Nathoo et al. proposed that although the decrease in CD36 expression 
associated with exposure to LPV/r in vitro may be beneficial to the patient because of 
decreased cytoadherence of parasitized erythrocytes, it could also make it more 
difficult for a patient’s innate immune system to fight P. falciparum infections 
because of reduced phagocytosis which also resulted from the diminished expression.  
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(72)  Perhaps antiparasitic action of the LPV/r occurs simultaneously with a reduction 
in the innate immune response to malaria, resulting in a null net benefit.   
 
3.  Strengths and limitations 
a.  Strengths 
This was the first time the effect of HIV PIs on malaria in humans has been 
studied.  We had the benefit of longitudenal data from two randomized controlled 
trials conducted by the Adult AIDS Clinical Trials Group with follow-up times 
exceeding two years.  The use of intent-to-treat analysis allowed us to assess the 
impact of LPV/r therapy without confounding by other factors; randomized 
experiments are generally regarded as the gold standard for estimating a causal effect.  
Additionally, the drug used in the comparison group (NVP) has previously 
demonstrated no antimalarial action (Tina 2004 JID, Redmond AIDS 2007) easing 
interpretation of our results.   
b.  Limitations 
Clinical malaria is not an ideal outcome.  The sensitivity and specificity of 
clinical syndrome when used to diagnose malaria are notoriously limited (91),Steve 
Taylor, personal communication).  The ACTG5208 study staff did not regularly 
collect blood smears as part of the protocol; instead they collected them when testing 
for malaria was appropriate based on the site’s standard of care guidelines.  The lack 
of systematically collected blood smears and the absence of information with regard 
to negative blood smears, made slide-positivity an unacceptable primary outcome.   
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As a part of our future research plan, we hope to explore sub-clinical malaria 
in the cohort of patients we used in this ancillary analysis.  This will require a 
serological definition of malaria.  Initially, antigen testing (specifically testing for 
HRP2) was considered, though we now believe the serum samples that are available 
to us from the ACTG5208 will not be appropriate.  Our laboratory collaborators are 
currently working on looking at antibody titers over time to identify acute malaria 
infections and using rapid diagnostic test kits; in the future PCR may also be 
considered.  In addition to providing information on sub-clinical disease, these types 
of data likely have greater sensitivity and specificity than clinical syndrome and may 
improve the reliability of our findings. 
An additional limitation stems from a potential causal intermediate.  The 
degree to which an individual is immunocompromized due to HIV, which is 
associated with  ART, may affect the risk of clinical malaria.(43, 45).  Women 
assigned to NNRTI-based therapy in Trial 1 were more likely to experience virologic 
failure when compared to women randomized to LPV/r-based therapy.(CROI 2009 
abstract)  This reduced control of HIV disease could have an impact on our findings 
as immune status could be in intermediate on the hypothesized causal pathway 
between PI-based ART and incidence of malaria.  
Finally, our study used a valid intent-to-treat analysis; though this is the gold 
standard statistically, information from an appropriately executed per-protocol 
analysis may have provided some additional information.  Among the 346 women 
included in this ancillary analysis, 50 (14%) switched treatments due to virologic 
failure or toxicity associated with the regimen to which she was randomized.  
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Because a relatively small percentage of patients switched treatments and because 
fewer then 10% of the malaria episodes occurred after the participant had switched, 
we anticipate that in this study, the difference between findings from intent-to-treat 
and per-protocol analyses may have been modest.   
 
4.  Implications 
 This work is only the first step in understanding what, if any, the effect of PI-
based therapy has on incidence of malaria in people infected with HIV.  We feel 
confidant in our findings which were generated from longitudenal, clinical trials data.  
Our finding of no effect was similar across trials and was the same when we 
conducted a sensitivity analysis in which only laboratory-confirmed cases were 
considered to have experienced malaria.   
 Even given our confidence in our results, we know that there are still many 
unanswered questions and do not conclude that looking at the effect of HIV PIs on 
malaria in humans is not still worthwhile.  Information on subclinical disease through 
the use of biomarkers will provide additional insight, as will looking at the clincal 
effect in children, who are at greater risk for malaria. 
 One important implication is that our findings suggest that there may be an 
insufficient overlap between results obtained in the laboratory and those generated in 
vivo to warrant additional laboratory studies that employ the same techniques. 
 
C.  Conclusions 
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Malaria remains a significant cause of morbidity and mortality.  This 
dissertation explored two specific challenges to the successful treatment of malaria, 
two small attempts to address what remains a complex and important problem.  We 
developed a novel way to estimate treatment efficacy and discovered that HIV PIs 
may not have antimalarial action in HIV-infected patients at risk of co-infection. 
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APPENDIX A:  Human Subjects 
The proposed research uses only simulated and de-identified data and is 
exempt from Institutional Review Board (IRB) review.  A decision to this effect for 
Aim 2 was issued by the UNC-Chapel Hill School of Public Health (Public Health 
IRB # 09-0221, 2/6/2009).  
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APPENDIX B: Greenhouse et al.’s calculation of Pmatch and their true recrudescence 
formulas(5) 
[Text and formulas adapted or taken directly from Greenhouse et al.(5)] 
Pmatch (the estimated probability of a match occurring by chance) was calculated as 
follows: The relative probability of all possible combinations of the number of alleles 
in the post-treatment sample was estimated by multiplying together the frequency of 
each of the component alleles in the combination. Each possible combination was 
then compared to the alleles present in the pre-treatment sample to determine if there 
was at least one allelic match. Pmatch was calculated by taking the sum of the 
probabilities of combinations that matched the pretreatment sample and dividing by 
the sum of the probabilities of all combinations. 
They estimated the number of true recrudescent infections by combining the 
following two equations.  
 
(1) 
where nor is the number of observed recrudescent infections, nrecru is the estimated 
number of true recrudescent infections, and nnew is the estimated number of true new 
infections, and  
 
(2) 
where nrp is the number of recurrent-parasitemia samples. By solving equation 2 for 
nnew, substituting this into equation 1, and solving for nrecru, we arrive at equation 3:  
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APPENDIX C: Formulas from Kwiek et al.(21)  
Participant-specific probability of a chance-match in indeterminate episodes with a 
single pre- and post-treatment shared band = 1 – (1 – y)x  where, 
Y is the prevalence of the shared band and X is the number of variants in the 
recurrent parasitemia sample 
 
Mean of participant-specific probabilities = Reinf 
Number of indeterminate infections = Ind 
Number of infections classified as recrudescent by genotyping = Recru 
Estimated failure rate = [((1-Reinf) x Ind) + Recru]/Total number of participants 
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APPENDIX D: MATLAB code adapted from code provided by Dr. Christina 
Burch, UNC – Chapel Hill. 
param=[];      
false_pos_rate=[]; 
for i = 1:10 
reps = 10000; 
argh = (i)*ones(reps,1); 
pea = (argh/10); 
init_infect1 = nbinrnd(argh,pea); 
re_infect1 = nbinrnd(argh,pea); 
param(i)=i; 
test1 = init_infect1 == re_infect1; 
false_pos_single(i) = sum(test1)/reps; 
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APPENDIX E: Format of the person-period dataset for discrete-time survival 
analysis 
Study ID Treatment Time Period D8 D12 D24 D48 Malaria 
1 1 8 1 0 0 0 0 
1 1 12 0 1 0 0 0 
1 1 24 0 0 1 0 1 
2 0 8 1 0 0 0 1 
3 1 8 1 0 0 0 0 
3 1 12 0 1 0 0 1 
4 0 8 1 0 0 0 0 
4 0 12 0 1 0 0 0 
4 0 24 0 0 1 0 0 
4 0 48 0 0 0 1 0 
 
Treatment: LPV/r-based therapy = 1; NNRTI-based therapy = 0 
Time period: number of weeks on study 
Dj: Time period indicator variables 
Malaria: Occurrence = 1; Non-occurrence = 0
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APPENDIX F: Discrete-time survival analysis: Modeling the relationship between 
the population discrete-time hazard function and study treatment  
 
logit hazardij = [α8D8 + α12D12 + α24D24 + α48D48] + β1(Treatment) 
 
α8D8 = baseline logit hazard function at week 8 
 
α12D12 = baseline logit hazard function at week 12 
 
α24D24 = baseline logit hazard function at week 24 
 
α48D48 = baseline logit hazard function at week 48 
 
β1 = slope parameter reflecting the effect of LPV/r-based therapy compared to 
NNRTI-based therapy on malaria  
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APPENDIX G. Numerical example of the adjustment of recrudescent infections 
 
Subjects in trial, N = 100 
Number of subjects with recrudescent infections as classified by PCR-correction = 15 
Number of subjects with reinfections as classified by PCR-correction = 30 
Y = Value sampled from distribution of the probabilities of false positives (in this 
example, Y = 0.17) 
Z = Value sampled from distribution of the probabilities of false negatives (in this 
example, Z = 0.25) 
 
Adjusted number of recrudescent infections = 15 – (15 x 0.17) + (30 x .25) 
   = 15 – 2.55 + 7.5 = 19.95 
PCR-corrected cure rate = 1 – (15/100) = 0.85 or 85% 
Cure rate adjusted for outcome misclassification = 1 – (19.95/100) = .8005 or 80.05% 
 
 
 
 
 
 
 
 
 
APPENDIX H.  Site and trial-specific survival curves for ACTG5208. 
 98 
 
 
 
Figure 1.  Survival curves for ACTG5208 participants in Eldoret, Kenya.  
(A) Trial 1.  (B) Trial 2.     
 
 
Figure 2.  Survival curves for ACTG5208 participants in Kericho, Kenya.  
(A) Trial 1.  (B) Trial 2. 
A B 
A B 
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Figure 3.  Survival curves for ACTG5208 participants in Lilongwe, Malawi.  
(A) Trial 1.  (B) Trial 2. 
 
  
Figure 4.  Survival curves for ACTG5208 participants in Kampala, Uganda.  
(A) Trial 1.  (B) Trial 2. 
A B 
A B 
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Figure 5.  Survival curves for ACTG5208 participants in Lusaka, Zambia.  
(A) Trial 1.  (B) Trial 2 
 
 
Figure 6.  Survival curves for ACTG5208 participants in Harare, Zimbabwe.  
(A) Trial 2.  No participants experienced malaria in trial 1. 
A B 
A 
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